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Abstract 
Background: Hereditary hypophosphatemia (HH) is a group of diseases 
characterized by monogenic hypophosphatemia due to reduced tubular maximum 
reabsorption of phosphate per glomerular filtration rate (TmP/GFR). This group 
includes X-linked dominant hypophosphatemic rickets (XLHR), caused by 
deactivating mutations in PHEX, autosomal dominant HR (ADHR), caused by 
activating mutations in FGF23 and autosomal recessive HR, caused by deactivating 
mutation in DMP1 (ARHR1) or ENPP1 (ARHR2), and all these conditions involve 
elevated levels of the phosphate regulating, bone-derived hormone FGF23. Combined 
therapy with phosphate and active vitamin D partially corrects rickets, osteomalacia 
and suboptimal growth in children, but the therapeutic window is narrow, with a risk 
of nephrocalcinosis and hyperparathyroidism. 
Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia 
hyperostosis syndrome (HHS) are caused by reduced levels of FGF23, due to 
deactivating mutations in FGF23, GALNT3 or KL. Phosphate lowering treatment only 
partially reduces the abnormal soft tissue calcifications characteristic for these 
conditions. 
Aims: To study hereditary disorders of phosphate metabolism in Norwegian patients, 
including the prevalence, phenotype and outcome of hereditary hypophosphatemia 
(HH) in the Norwegian pediatric population. Moreover, to study the genetic causes, 
including mutations in novel genes, associated with hypo- or hyperphosphatemia in 
Norwegian families. 
Materials and methods: Patients were recruited by contact with all pediatric and 
medical departments in Norwegian hospitals during the years 2009-2015. Inclusion 
criteria for HH were hypophosphatemia and reduced TmP/GFR, and for HFTC/HHS 
hyperphosphatemia and increased TmP/GFR. Clinical data were retrieved from the 
patients’ medical records. If the genotype was not already known, we performed 
Sanger sequencing of the PHEX, FGF23, DMP1, ENPP1, GALNT3, KL and 
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FAM20C genes. Whole exome sequencing was performed in three families where the 
genetic screening was negative. 
Results: In Paper I we found a prevalence of genetically verified XLHR in Norway 
of 1 in 60.000. PHEX mutations were confirmed in 21 of the 28 included patients 
with HH, FAM20C mutations in two, and SLC34A3 mutations in one patient. We 
found a trend for XLHR males to be more growth restricted and more often having 
dental involvement than females. In XLHR children, 10 of 15 patients had elevated 
PTH before the start of treatment and nine of 21 had low-grade nephrocalcinosis 
during treatment with phosphate and alfacalcidol, but only one case of transiently 
compromised renal function. 
In Paper II we identified novel combined heterozygous mutations in FAM20C in two 
male siblings with hyperphosphatemia and reduced TmP/GFR, and elevated levels of 
FGF23. They did not demonstrate rickets, but rather generalized osteosclerosis and 
intracerebral calcifications. 
In Paper III we identified a novel homozygous mutation in GALNT3 in two siblings 
with HFTC and HHS. We showed the phenotypic diversity within the same family, 
and the fluctuation of symptoms over time. We also reviewed all cases of genetically 
verified HFTC and HHS, and showed that the combined HFTC/HHS phenotype is 
more common than previously recognized. 
Conclusions: We have shown that the prevalence of XLHR in Norwegian children 
seems to be lower than reported in other cohorts. In XLHR children, males seem to 
have a more severe mineralization phenotype than females. Adequate treatment 
partially corrects rickets, skeletal axis deviation and longitudinal growth, but gives an 
increased risk of low-grade nephrocalcinosis, although without renal dysfunction. We 
have also identified two patients with FAM20C mutations and shown that they have 
pathological serum levels of FGF23, and that FAM20C mutations are associated with 
autosomal recessive FGF23-dependent hereditary hypophosphatemia. Finally, we 
have brought further support to theory that HFTC and HHS are two syndromes in a 
clinical spectrum of FGF23 related hereditary hyperphosphatemias. 
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X-linked hypophosphatemic rickets was first described by Fuller Albright in 1937, as 
rickets resistant to vitamin D therapy (1). Since then, the knowledge on the group of 
diseases known as hypophosphatemic rickets, as well as details in the regulation of 
phosphate mineral homeostasis, has greatly advanced. 
 
1.1 Historical perspective 
Rickets, a bone deforming disorder seen in children, emerged as a prevalent condition 
during the industrial revolution in Northern Europe in the 1600s, and was first 
described by Daniel Whistler in the year 1645 (2). The word “rickets” is of uncertain 
origin, but might come from the English word “wrick”, or the Swedish word “ricka” 
meaning to sway (3). It might also come from the Greek word meaning “in or of the 
spine”. The link between rickets and the lack of sun exposure to skin was described in 
1822; the high degree of air pollution and high buildings in industrialized cities, 
combined with a vitamin D deficient diet, lead to evidence of rickets in 80-90 % of 
children in Northern Europe and Northeastern United states around year 1900 (4).  
 
The introduction of vitamin D supplements and vitamin D fortified milk greatly 
reduced the prevalence of this condition. In Norway, consumption of cod-liver oil has 
traditionally been an important dietary source of vitamin D, leading to a relatively 
lower prevalence of vitamin D deficiency; A survey from 1931 showed that 50 % of 
children below two years of age in the northernmost county of Norway had clinical 
signs of rickets (5).  
 
Rickets resistant to high doses of vitamin D was first described by Albright in 1937, 
and the familial occurrence of Vitamin D-resistant rickets (VDRR) was first 
recognized by Christensen in 1940 (6). An X-linked inheritance pattern was proposed 
by Winters et al. in1958 (7), but later also autosomal dominant (8) and autosomal 
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recessive (9, 10) inheritance patterns were recognized. In 1976 Eicher et al. 
constructed the Hyp mouse, the murine model of X-linked hypophosphatemic rickets 
(XLHR) (11), and ten years later the disease was mapped to the short arm of 
chromosome X in humans (12). Since then, the knowledge on pathophysiology and 
genetic diversity has increased significantly. 
 
1.2 Phosphate homeostasis 
Until recently the regulation of body phosphorus was thought to be secondary to the 
regulation of serum-calcium (S-Ca). However, the identification of fibroblast growth 
factor 23 (FGF23) as a specific phosphate regulating substance, a phosphatonin, has 
contributed to increased understanding of phosphate regulation in health and disease. 
  
1.2.1 Phosphate in the body 
The adult human body contains about 700-900 g of phosphorus, of which 85 % is 
contained in bone tissue as hydroxyapatite [Ca5(PO4)3(OH)] (13). About 14 % is 
localized intracellularly as organic phosphate compounds serving important functions 
in cellular energy metabolism (adenosine triphosphate and adenosine diphosphate; 
ATP and ADP), as genetic material (DNA and RNA), in intracellular signaling 
cascades (e.g. cyclic adenosine monophosphate; cAMP) and as cellular structures 
such as phospholipids of the cellular membrane. Intracellular enzymatic activity and 
cell signaling are also regulated by phosphorylation and dephosphorylation. Inorganic 
phosphate (H2PO4-/HPO42-) is also the most important intracellular anion with an 
intracellular concentration of about 100 mmol/L, and serves as a buffer. Less than 1 
% of total body phosphorus is found in extracellular fluids as phospholipids, 
phosphoesters and serum inorganic phosphate (S-P) (13).  The concentration of S-P is 
approximately 1 mmol/L, depending on age and sex (Table 4, in the Appendix), and 
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the higher S-P in children is probably a physiological adaptation to ensure availability 
of phosphorus for mineralization of growing bone (14). 
 
Phosphate is abundant in most foods, and the average adult ingests about 1 g of 
phosphate per day, of which 90 % is absorbed in the small intestine. The elimination 
of phosphorus from the body is through the kidneys. The filtered load of phosphorus 
is about 6 g per day, and most is reabsorbed in the proximal tubules. In steady state, 
the net excretion in urine equals intestinal absorption (13). 
 
1.2.2 Phosphate transporters 
The transportation of phosphate across cell membranes occurs through mainly two 
families of sodium phosphate cotransporters, type II and III sodium phosphate 
cotransporters (NaPi-II and NaPi-III) (15), encoded by the solute carrier 34 (SLC34) 
(16) and SLC20 genes (17), respectively. Both families belong to the SLC 
superfamily of membrane transporters (18), and uses the inward electrochemical 
gradient for Na+, generated by the Na/K-ATPase, for secondary-active transport of 
phosphate. The SLC17 (type I Na/Pi cotransporter) family was earlier thought to be 
important for phosphate membrane transport, but these transporters are not strictly 
Na/Pi cotransporters, and are implicated in transport of organic anions and amino 
acids (19). 
 
SLC34/Type II Na/Pi cotransporters  
The type II sodium phosphate cotransporter family includes three members, NaPi-IIa, 
NaPi-IIb and NaPi-IIc, encoded by the SLC34A1, SLC34A2 and SLC34A3 genes 
respectively. NaPi-IIa and NaPi-IIc are located in the apical membrane of kidney 
proximal tubule cells (20), and the cotransport of Na+ and HPO42- is coupled to the 
energy dependent Na/K-ATPase on the basolateral cell surface, generating an inward 
gradient for Na+, driving the transport of Na and HPO42- on the apical surface.  
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The final step in the regulation of phosphate reabsorption is by regulating the 
expression of NaPi-IIa and NaPi-IIc in the brush border membrane in the proximal 
tubuli. Both parathyroid hormone (PTH) and FGF23 act on receptors on the 
basolateral cell surface, inducing intracellular signaling cascades leading to increased 
endocytosis and lysozymal degradation of the transporters (21). This decreases 
reabsorption of Pi from filtered urine, whereas hypophosphatemia and 1,25 
dihydroxyvitamin D (1,25(OH)2D) stimulates phosphate reabsorption (21). There also 
seems to be a directly regulating effect of dietary Pi on Na/Pi cotransport in proximal 
tubules; feeding rats a high phosphate diet lead to internalization of NaPi-IIa and IIc 
from the renal brush border membrane within a few hours (22). 
 
The NaPi-IIb is located to the apical surface of enterocytes of the small intestine, as 
well as in cells of the lung, liver, testes and colon (23). It is the most important 
transport system for active Pi absorption in the small intestine (24), and is up-
regulated in response to a low-phosphate diet and 1,25(OH)2D (25).  Homozygous 
mutations in SLC34A2 have been associated with pulmonary alveolar microlithiasis 
(26, 27). 
 
SLC20/Type III Na/Pi cotransporters  
The type III sodium phosphate cotransporter family includes two members, Pi 
transporter 1 (PiT-1) and PiT-2, encoded by the SLC20A1 and SLC34A2 genes, 
respectively (17). They were first recognized as the retroviral receptors Glvr-1 and 
Ram-1, but were later shown to be Na/Pi cotransporters with a wide tissue 
distribution (17, 28), and they probably serve housekeeping functions of phosphate 
metabolism (18). Importantly, PiT-1 seems to play a role in transportation of 
inorganic phosphate into osteoblasts (29), and may thus serve important functions in 
the mineralization process. PiT-2 has been localized to the proximal tubule brush 
border membrane in rats, with the expression level regulated by dietary phosphate 
load (30). Thus, PiT-2 could explain the residual phosphate reabsorption in the 
proximal tubule of NaPi-IIa and NaPi-IIc double knockout mice (31), but the 
functional importance of PiT-2 in phosphate reabsorption remains unclear (18). 
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1.3 Regulation of phosphate 
The important functions of phosphate in cell physiology discussed above, implies 
tight regulation of phosphate homeostasis. Short term regulation of serum phosphate 
is achieved by fast shifts of phosphate in and out of cells, while long term regulation 
of serum- and body phosphate is a complex interplay between several hormones and 
factors, including parathyroid hormone (PTH), 1,25(OH)2D and FGF23 (32). Proper 
mineralization of growing and remodeling bone is dependent on the availability of 
calcium and phosphorus, whereas to high levels of these to minerals in extracellular 
fluids poses a risk for ectopic calcifications. Calcium- and phosphorus regulation are 
therefore tightly coupled. However, in addition to the PTH/vitamin D-axis acting 
primarily to maintain normocalcemia (Figure 1), serum phosphate is regulated 
specifically by the FGF23 dependent bone/kidney axis (Figure 2).  
1.3.1 Parathyroid hormone 
PTH is a peptide hormone synthesized in and secreted by the chief cells of the four 
parathyroid glands to restore normocalcemia in response to small decrements in 
serum ionized calcium (33). Reduced binding of calcium to the seven-transmembrane 
G-coupled calcium sensing receptor (CaSR) located on the cell surface, increases 
PTH production and release, while binding of calcium to the CaSR leads to inhibition 
of PTH secretion. PTH promotes bone resorption and mobilizes calcium and 
phosphorus from bone, and also directly increases reabsorption of calcium from 
filtered urine through the TRPV5 (34). By stimulating the renal 1-α-hydroxylase to 
increase conversion of 25OHD to 1,25(OH)2D, PTH indirectly increase 
gastrointestinal absorption of calcium, and to a lesser degree phosphate (33). 
 
PTH secretion is also regulated by several other factors involved in mineral 
metabolism. Reduced levels of 1,25(OH)2D, via reduced intestinal calcium 
absorption, lead to increased synthesis and secretion of  PTH, while increased levels 
of  1,25(OH)2 D have a direct inhibitory effect on transcription of the PTH gene (33) 
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Figure 1 The parathyroid acts as a calciostat. 
The primary stimulus for PTH secretion by the parathyroid gland is a reduced serum 
level of free ionized calcium (33). PTH act on bone to cause resorption with efflux of 
calcium and phosphorus, and act on the kidney to increase the activity of the alpha-
hydroxylase, suppress phosphate reabsorption through the NaPi-IIa/c and increase 
the reabsorption of calcium through the TRPV5 (34). Increased level of 1,25(OH)2 D 
leads to increased absorption of calcium and phosphorus from the gastrointestinal 
tract. The net result is to restore normocalcemia, while simultaneously avoiding 
hyperphosphatemia. The elevated level of S-Ca increases the activity of the CaSR, 
reducing PTH synthesis and secretion (33), closing the negative feedback loop. 
 
The effect of PTH on body phosphate homeostasis is opposite of the effect on 
calcium; PTH down-regulates the expression of the NaPi-IIa and IIc cotransporters in 
the renal proximal tubules (35, 36), reducing renal reabsorption of phosphate, 
probably to counteract an elevation in the serum calcium-phosphate product and the 
risk of ectopic calcifications. Conversely, increased serum phosphate levels stimulate 
production and secretion of PTH, both due to phosphate binding of free calcium to 
decrease serum ionized calcium (37), as well as by a direct of phosphate on the 
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parathyroid gland (38). Secondary hyperparathyroidism is a well-known complication 
of chronic renal failure with chronically elevated serum phosphate levels. 
 
The effect of PTH on bone tissue is dual; continuously elevated PTH has a catabolic 
effect on bone, while pulsatile elevation of PTH actually has anabolic effect (39). 
 
 
Figure 2 Bone acts as a phosphostat. 
Secretion of FGF23 is stimulated by elevated levels of serum phosphate and 
1,25(OH)2D (40). FGF23 binds to the FGFR1/α-klotho receptor complex in the 
proximal tubule of the kidney, leading to down-regulation of phosphate transporters 
NaPi-IIa and NaPi-IIc and inhibition of the α-hydroxylase (41). FGF23 also bind 
FGFR1/α-klotho receptor in the distal convoluted tubule (42) to increase calcium 
reabsorption through the TRPV5 (43). The reduced levels of 1,25(OH)2D leads to 
reduced absorption of calcium and phosphorus in the small intestine. 
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1.3.2 Vitamin D 
Vitamin D in its active form, 1,25(OH)2D is an important intracellular hormone with 
a wide range of physiological effects, and vitamin D deficiency and insufficiency is 
thought to have implications for a wide range of diseases (44). Historically, however, 
vitamin D deficiency has been linked primarily to rickets, as 1,25(OH)2D is important 
for absorption of calcium, and to a lesser degree phosphorus, from the small intestine.  
 
In the skin, UVB irradiation converts 7-dehydrocholesterol to cholecalciferol and 
further to provitamin D. In the liver, provitamin D is hydroxylated in the 25-position 
to 25OHD (calcidiol) (44). However, the active metabolite of vitamin D is the 
1,25(OH)2D (calcitriol), which is produced by hydroxylation in the 1-position by 1-α-
hydroxylase (CYP27B1) in the kidney proximal tubule cells. 
 
1,25(OH)2D acts intracellularly, and binds to Vitamin D responsive elements (VDRs) 
involved in gene regulation. In mineral metabolism, the main effect of 1,25(OH)2D is 
to increase the absorption of Ca2+ (45) and to a lesser extent also PO43- (25) in the 
small intestine. In vitamin D deficiency, however, there is initially a low serum 
calcium level while serum phosphate level remains normal. However, this 
hypocalcaemia leads to increased production and secretion of PTH, which stimulates 
the conversion of 25OHD to 1,25(OH)2D and also inhibits renal reabsorption of 
phosphate. Thus, vitamin D deficiency negatively effects bone metabolism, most 
importantly through reducing availability of calcium and phosphate for skeletal 




FGF23 has emerged as a key hormone in the bone/kidney-axis of phosphate 
regulation, and the knowledge on the physiological and pathophysiological 
mechanisms involving FGF23 is rapidly increasing.  
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The 22 members of the human fibroblast growth factor (FGF) gene family can be 
categorized according to their mode of function, as intracrine/intracellular, 
paracrine/canonical and endocrine (47). The intracellular FGFs in the 
FGF11/12/13/14 subfamily, have no signal peptide sequence, and are therefore not 
secreted, but work intracellularly on voltage gated sodium channels to regulate the 
electrical excitability of neurons and possibly other cell types (48). The paracrine 
FGFs comprise the FGF1/2/5, FGF3/4/6, FGF8/17/18, FGF7/10/22 and FGF9/16/20 
subfamilies. They harbor a signal peptide, and are thus exported from the cell, but 
also have binding sites for heparin and interact with heparin-like molecules in the 
extracellular environment, and do not enter systemic circulation (47). The paracrine 
FGFs are important in embryogenesis, as demonstrated in human diseases caused by 
loss-of-function mutations in some of these FGFs (49-51).  
 
The endocrine FGF19, FGF21 and FGF23, also have an n-terminal signal peptide, but 
their affinity for heparin-like molecules is very low, and they therefore escape the 
extracellular matrix and enter systemic circulation (52). The fibroblast growth factor 
receptor (FGFR) gene family comprises four genes encoding FGFR1-4, and the 
actions of the endocrine FGFs are mediated mainly through binding FGFR1 and 
FGFR4, with α- and β-klotho, respectively, as obligate cofactors to increase receptor 
binding affinity (52).  
 
FGF23 was first identified as a secreted protein expressed in the mouse brain (53), 
and mutations in the human FGF23 gene were found to be associated with autosomal 
dominant hypophosphatemic rickets (ADHR) (54). It very soon became clear that 
FGF23 is the factor responsible for the phosphate wasting phenotype seen in tumor 
induced osteomalacia (TIO) (55), and that in ADHR, mutations altering the arginine 
residues in position 176 or 179 of the furin protease cleavage site, R176XXR179 in exon 
3, make the protein resistant to enzymatic break down (56). Osteoblasts are the main 
source of FGF23 production (57), which is stimulated by increased levels of serum 
phosphate and 1,25(OH)2D (40). 
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FGF23 mediate effects through binding to FGFR1c with α-klotho as an obligate 
cofactor (58). FGF23 may also bind to FGFR3 and FGF4 (59), but the functional 
significance of this binding is unknown (60). The organ and cell specificity of FGF23 
action is determined by the tissue expression of FGFR1c and α-klotho. The most well 
defined actions of FGF23 are in the kidney; FGF23 binds to the FGFR1c/α-klotho 
receptor complex expressed on the basolateral surface of proximal tubuli cells, 
activating the extracellular signal-regulated kinase 1/2 (ERK1/2) – 
serum/glucocorticoid-regulated kinase 1 (SGK1) intracellular signaling pathway (61). 
This leads to phosphorylation of Na+/H+ exchange regulatory factor (NHERF)-1 
(61), a scaffolding protein responsible for binding NaPi-IIa and localizing the 
transporter on the luminal surface of the proximal tubuli cells (62). Phosphorylated 
NHERF-1 dissociates from the luminal cell membrane, leading to internalization and 
thus reduced expression of the NaPi-IIa on the luminal surface of the proximal tubuli 
cells (61). The FGF23/FGFR1c/α-klotho complex also leads to down regulation of 
the kidney 1-α-hydroxylase (Cyp27b1) responsible for converting 25OHD into its 
active metabolite 1,25(OH)2D (41), and up regulation of the 24-hydroxylase 
(CYP24A1) responsible for conversion of 25OHD to the inactive metabolite 
24,25(OH)2D (63). 
 
1.4 Bone metabolism 
Development  
During embryogenesis the skeletal system develops mostly from mesodermal cells, 
but the facial skeleton is derived from neural crest cells of the embryo. The cells 
destined for skeletal development differentiate into fibroblasts, chondroblasts or 
osteoblasts. Bone can develop through two different processes. Intramembranous 
ossification is the process where mesenchyme in the dermis develops directly into 
bone tissue, as in the flat bones of the skull. Most of the skeleton, however, develops 
through enchondral ossification. In this process a cartilage model of the bone is first 
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laid down, with secondary apoptosis of chondrocytes and replacement by bone 
forming osteoblasts (64).   
 
Growth 
Skeletal growth occurs at the growth plates, physes, at the distal and proximal ends of 
long bones (Figure 3).  As illustrated in Figure 4, the chondroblasts resting in the 
germinal zone will start proliferate and arrange in columns. Differentiation into 
mature chondrocytes with production of cartilage matrix occurs in this zone. In the 
hypertrophic zone, the chondrocytes fully mature and grow in size, increasing the 
length of the cartilage. However, as the chondrocyte hypertrophies the cartilage 
matrix diminishes and calcifies, resulting in chondrocyte apoptosis in the zone of 
enchondral ossification. Capillaries and osteprogenitor cells invade the lacunae 
surrounding the apoptotic chondrocytes. Osteoblasts differentiate and lie down 
osteoid on the trabeculae of remaining cartilaginous matrix (65). As the bone grow in 
length, the bony trabeculae of the metaphysis are resorbed by osteoclasts, and the 
trabecular bone is substituted by lamellous, cortical bone of the diaphysis. In this 
way, the width of the metaphysis and epiphysis remains stable as the bone grows, 
while the diaphysis increases in length. Failure of apoptosis of the late hypertrophic 
chondrocytes of the physis leads to an expansion of the growth plate, seen clinically 
as the widening of the physis characteristic for rickets (66). 
 
Remodeling 
The hormonal changes associated with puberty make the growth plates mineralize, 
and longitudinal growth stops. However, bone is continuously renewed during life to 
accommodate the pattern of stress put on them, and also as a part of mineral 
metabolism, a process called remodeling. Remodeling is a cyclic process that takes 
place in small units. In the remodeling cycle, osteoclasts are activated and start 




Figure 3 Growth plates 
The figure gives an overview of the growth plates of the upper and lower limb, and 
their relative contribution to longitudinal growth (Based on figure from The Royal 
Children’s Hospital Melbourne; http://www.rch.org.au/fracture-
education/remodelling/). 
 
Bone formation and mineralization 
In the process of bone formation, the osteoblasts first synthesize new bone matrix, 
and then regulate matrix mineralization by releasing membrane bound vesicles 
containing calcium and phosphorus (68, 69). Bone matrix consists mainly of fibers of 
type I collagen arranged in a multiple layers with alternating orientation to increase 
bone strength. About 10 – 15 % of bone matrix consists of non-collagenous proteins, 
mostly osteoblast-derived, but also serum-derived. The non-collagenous proteins 
probably serve various functions in regulating bone mineralization, osteoblast- and 
osteoclast proliferation, differentiation and activity (70). Table 1 gives an overview of 
bone matrix proteins.  
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Figure 4 The growth plate 
The figure gives a schematic overview of the growth plate. Chondroblasts rest in the 
germinal zone. In the proliferative zone, the chondrocytes arrange in columns, with 
surrounding cartilage matrix. In the hypertrophic zone, the chondrocytes mature and 
grow in size, increasing the length of the cartilage. However, as the chondrocyte 
hypertrophies the cartilage matrix diminishes and calcifies, resulting in chondrocyte 
apoptosis in the zone of enchondral ossification. Capillaries and osteprogenitor cells 
invade the lacunae surrounding the apoptotic chondrocytes. Osteoblasts 
differentiate and lie down osteoid on the trabeculae of remaining cartilaginous 
matrix. Illustration adapted from http://www.uptodate.com. 
 
Minerals, mainly hydroxyapatite, make up 50-70 % of bone (67). The solubility of 
hydroxyapatite makes bone resorption an important source of serum calcium and 
phosphate in the mineral homeostasis. Osteoblasts synthesize matrix extracellular 
vesicles in which the concentration of calcium and phosphate is much higher than in 
extracellular fluid (68). Proteins, phospholipids, calcium and phosphate in the 
vesicles complex to form a mineralization nucleation core, on which further growth 
of hydroxyapatite crystals can take place. The vesicles are deposited in the 
extracellular matrix, at the ends of the collagen fibrils. DMP1 and bone sialoprotein 
are known to be important for the development of the nucleation core of the matrix 
extracellular vesicles, and ALP, osteocalcin and osteopontin are also involved in 
regulation of matrix mineralization (67). 
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Table 1 Bone matrix proteins  
Protein 
families 
 Proteins  Function 
Collagen 
 
Type I collagen 
 - Primary ECM component of bone tissue 
- Nucleation site for mineral 
- Influences post-yield behavior 
- Promotes osteogenesis 
- Osteoclast binding and degradation 
 Type III collagen  - Promotes bone formation 
Matricellular 
proteins 
 TSP 1  - Cell attachment 
 TSP 2  - Cell attachment 
 SPARC  - Collagen fibrilogenesis 
 R-spondins  - Osteoblast regulating 
SIBLING 
 BSP  - Promotes matrix mineralization 
 
DMP1 
 - Robust osteocyte marker 
- Regulates phosphate metabolism 
- Involved in osteocyte function 
 MEPE  - Regulates phosphate metabolism 
 Osteopontin  - Inhibits bone mineralization - Promotes bone resorption 
Carboxylated 
proteins 
 Osteocalcin  - Robust marker of osteoblast differentiation - Inhibits mineralization 
 MGP  - Inhibits mineralization 
 Periostin  - Regulates SOST - Influences tenascin-C and fibronectin 
SLRP 
 Asporin  - Promotes mineralization 
 Biglycan  - Decreases active TGF-beta availability - Promotes normal collagen fibrillogenesis 
 Decorin  - Decreases active TGF-beta availability - Promotes normal collagen fibrillogenesis 
 Keratocan  - Regulates collagen fibrillogenesis - Regulates mineralization 
MMP  MMP2  - ECM degradation for lacunar-canalicular network 
 MMP14   - Differentiation of osteoblasts 
Adapted from (70). Abbreviations: ECM = extracellular matrix; TSP = 
Thrombospondin; SPARC = secreted protein acidic and rich in cysteine; SIBLING = 
small integrin-binding ligand n-linked glycoprotein; BSP = bone sialoprotein; DMP1 
= dentin matrix protein 1; MEPE = matrix extracellular phosphoglycoprotein; SOST 
= gene encoding Sclerostin; SLRP = small leucine rich proteoglycans; TGF = 
transforming growth factor; MMP = matrix metalloproteinase. 
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Defective mineralization; rickets and osteomalacia 
Rickets is a disease of childhood, with defective mineralization of bone matrix at the 
growth plate, leading to skeletal growth disturbance. Inadequate mineralization of 
newly formed osteoid in bone remodeling, leads to softening of bones, osteomalacia, 
in both children and adults (66). Hypophosphatemia in the environment of the 
hypertrophic chondrocytes at the growth plate is the common denominator of all 
rickets (66). Hypophosphatemia inhibits apoptosis of hypertrophic chondrocytes. The 
growth plate will expand because of hypertrophy, and fail to mineralize. At the same 
time, there is osteomalacia, or failure to mineralize newly formed osteoid in the 
continuously remodeling skeleton. In children there will be both rickets and 
osteomalacia, while after closure of the epiphyses, there will only be osteomalacia 
(66). 
 
1.5 Hereditary hypophosphatemia 
Hereditary hypophosphatemia (HH) refers to a group of monogenic disorders 
characterized by hypophosphatemia caused by reduced tubular maximum 
reabsorption of phosphate per glomerular filtration rate. Historically, these conditions 
have been referred to as hypophosphatemic rickets. However, it has now become 
clear, that this group of disorders includes several disorders with similar 
pathophysiology, with or without rickets. 
 
1.5.1 Hereditary hypophosphatemic rickets 
X-linked hypophosphatemic rickets (XLHR) was first described as rickets resistant to 
vitamin D therapy (1). Since then, the discovery that mutation in several genes are 
associated with HR has given new insight into phosphate metabolism and the group 
of diseases known as hypophosphatemic rickets.   
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X-linked hypophosphatemic rickets 
X-linked hypophosphatemic rickets (XLHR) is the most common variant of HR, with 
a reported prevalence of 1 in 20.000 (71, 72). The gene responsible for XLHR was 
identified by positional cloning in 1995 (73); inactivating mutations in the PHEX 
gene (Phosphate-regulating endopeptidase homolog on the X-chromosome; OMIM * 
300550) causes this X-linked dominant condition. The PHEX gene consists of 22 
exons with large intronic regions (74) and encodes a transmembrane protein of the 
type II integral membrane zinc-dependent endopeptidase family. The highest 
expression is found in mature osteoblasts and odontoblasts, but the gene is also 
expressed in the kidney. XLHR is associated with elevated levels of fibroblast growth 
factor-23 (FGF-23) (75-77), but FGF23 is not a substrate for PHEX, and the exact 
mechanism for PHEX mutations leading to elevated FGF23 levels is not known. The 
C-terminal end of the mineralized matrix small integrin-binding ligand n-linked 
glycoproteins (SIBLINGs) contains an acidic serine aspartate-rich MEPE-associated 
motif (ASARM) (78). It has been shown that free ASARM peptides in the 
phosphorylated form (pASARM), inhibits mineralization of bone matrix by binding 
hydroxyapatite (79). Normally pASARM is a substrate for PHEX (79), and this could 
explain the hypomineralization of bone and dentin in XLHR. The Hyp mouse is a KO 
model of XLHR, with phenotypic features including osteomalacia, growth defects, 
down regulation of the mural kidney sodium-phosphate cotransporter type 2 (NPT2), 
and increased levels of serum FGF23 (80).  
  
To date, over 300 different mutations in the PHEX gene has been reported in XLHR 
(PHEX mutation database: http://www.phexdb.mcgill.ca/), and includes missense, 
nonsense, splice mutations, small insertions or deletions, as well as large deletions or 
insertions of parts of or multiple exons. The mutations also seem to be fairly evenly 
distributed all over the coding part of the gene, but pathogenic mutations in the 
5’UTR (81) and 3’UTR (82), as well as in the introns of the gene, have been reported.  
 
The clinical presentation in XLHR is highly variable; in pedigrees with affected 
parents, affected children are often diagnosed in infancy upon screening for 
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hypophosphatemia combined with a low TmP/GFR, before development of 
symptoms (83). However, as many cases of XLHR represent de novo mutations, 
children may present with short stature, delayed walking, bone pain, a waddling gait 
and varus of the lower extremities (84). In these cases radiological examination often 
shows rickets of the wrists, knees and ankles. Dental involvement is evident as 
spontaneous periapical abscesses, and dental examination shows high pulp horns, 
intraglobular dentin, and mineralization defects of dentin. The primary teeth are most 
commonly affected, whereas adequate treatment can improve mineralization of 
permanent teeth in some cases (85). Adolescents and adults may complain of bone 
pain, and some develop enthesopathies (ectopic calcification of tendons). In addition 
to the combination of hypophosphatemia and hyperphosphaturia, the blood tests 
before the onset of treatment show a serum level of alkaline phosphatase that is often 
raised in children (86), the level of 1,25(OH)2D is low or inappropriately normal 
given the hypophosphatemia, whereas the levels of serum intact PTH is normal or 
slightly elevated, even before the onset of therapy (87-89). Serum calcium and urine 
calcium/creatinine ratio are normal before the start of treatment. 
 
Autosomal recessive hypophosphatemic rickets 
Earlier, only mutations in the DMP1 gene (dentin matrix acidic phosphoprotein 1). 
were associated with autosomal recessive hypophosphatemic rickets (ARHR). 
However, recent research has shown that ARHR can also be caused by mutations in 
the ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) (90, 91), and these 
conditions are now referred to as ARHR1 and ARHR2, respectively. 
  
ARHR1 
The DMP1 gene (OMIM * 600980) was identified as the cause of ARHR1 in 2006 
(10), and since then only a few homozygous or compound heterozygous mutations 
have been reported (9, 10, 92-97). DMP1 consists of 6 exons on chromosome 4q21, is 
highly expressed in osteocytes, and is a member of the ‘SIBLING’ (small integrin 
binding ligand n-linked glycoprotein) family of non-collagenous extracellular matrix 
proteins involved in bone mineralization (98). The Dmp1 knockout model displays 
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rickets and osteomalacia with isolated renal phosphate wasting associated with 
elevated FGF23 levels and normal U-Ca/creatinine ratio (U-Ca/Crea-ratio) (9).  The 
phenotype is similar to that seen in XLHR, but ectopic calcifications are more typical 
for this condition, with hyperostosis of the long bones and the scull base as well as 




ARHR2 is caused by recessive mutations in ENPP1 (90, 91), which has also been 
identified as the cause of the lethal condition generalized arterial calcifications of 
infancy (GACI) (99, 100). Identical mutations can cause GACI or FGF23-dependent 
hypophosphatemic rickets in different subjects within the same family (91), while 
some subjects display a combined phenotype with both arterial calcifications and 
simultaneous renal phosphate loss (101), leading to an attenuated GACI phenotype 
with prolonged survival.  
 
The ENPP1 gene (OMIM*173335) is located on chromosome 6q22-q23 and 
comprises 23 exons. ENPP1 is a type II transmembrane glycoprotein responsible for 
hydrolyzation of extracellular adenosine triphosphate (ATP) to generate inorganic 
pyrophosphate (PPi) and adenosine monophosphate (AMP) (102). PPi is an inhibitor 
of hydroxyapatite crystal growth (Figure 7) (103), and also suppress chondrogenesis 
(104). Recessive mutations in ENPP1 thus lead to lower levels of PPi and a pro-
mineralizing state, which is reflected by GACI and by ossification of the posterior 
longitudinal ligament seen in humans with ARHR2 (105) and in Enpp1 mutant mice 
(106). Mutations in ENPP1 have also been associated with susceptibility to insulin 








Figure 5 ENPP1 is involved in mineralization regulation.  
A) In the physiological state ENPP1 hydrolyzes extracellular ATP to generate AMP 
and pyrophosphate (PPi). PPi is a substrate for the tissue nonspecific alkaline 
phosphatase (TNAP), which hydrolyses PPi to generate inorganic phosphate (Pi). 
Pi and calcium (Ca2+) chelates in hydroxyapatite crystals, but PPi is an inhibitor of 
this mineralization process, and there is balanced mineralization. B) Mutations in 
ENPP1 lead to lower levels of PPi and a pro-mineralizing state reflected by GACI 
and by ossification of the posterior longitudinal ligament seen in humans with 
ARHR2 and in the Enpp1 mutant mice. 
 
Autosomal dominant hypophosphatemic rickets 
Autosomal dominant hypophosphatemic rickets (ADHR) was fully characterized as a 
separate entity in 1997 (108), and activating mutations in the FGF23 gene 
(OMIM*605380) were later identified as the cause of this disorder (54). The FGF23 
gene is located on chromosome 12 and comprises 3 exons (Figure 6). Exon 3 harbors 
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a furin protease cleavage site, R176XXR179, and mutations altering the arginine 
residues in position 176 or 179 make the protein resistant to enzymatic break down 
(56). The resulting elevated levels of intact FGF23 (iFGF23) are responsible for the 
phenotype seen in ADHR, as well as in XLHR and ARHR, and the three conditions 
have a quite similar clinical presentation, as described above. Remarkable for ADHR, 
however, is the delayed onset of symptoms until after puberty or pregnancy observed 
in some females, as well as spontaneous remission of symptoms and biochemical 




Figure 6 FGF23 gene and protein structure. 
The FGF23 gene comprises 3 exons encoding the 251 amino acids of FGF23. The 
protein has a signal peptide encoded by exon 1. The subtilisin proprotein 
convertase (SPC) recognition site encoded by exon 3 contains the furin protease 
cleavage site. Mutations altering the arginine residues in position 176 or 179 make 
the protein resistant to enzymatic break down. 
 
Hereditary hypophosphatemic rickets with hypercalcuria 
Hereditary hypophosphatemic rickets with hypercalcuria (HHRH), first described in 
1985 (109), is caused by homozygous or compound heterozygous mutations in the 
SLC34A3 gene (OMIM*609826), encoding the type IIc sodium-phosphate 
cotransporter (NaPi-IIc) (110, 111). There is no general tubulopathy, but the 
hypophosphatemia leads to a compensatory up-regulation of 1,25(OH)2D with 
increased intestinal absorption of calcium and phosphate, finally resulting in 
hypercalcuria. The level of intact FGF23 has been reported as suppressed (112) or 
low normal (113). Hypophosphatemia can lead to rickets and osteomalacia, and the 
high calcium-phosphate product in urine leads to nephrolithiasis and 
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nephrocalcinosis. However the phenotype is highly variable, including the degree of 
reduced phosphate reabsorption in individuals with heterozygous mutation. 
Interestingly, while mutations in the murine orthologoue of SLC34A3 do not have a 
similar effect in animal models, NaPi-IIa double knockout mice have a phenotype 
resembling HHRH, except from rickets and osteomalacia (114). NaPi-IIc thus seems 
to play a less important role in murine proximal tubular phosphate resorption than in 
humans (115). In humans, there are a few reports of autosomal dominant mutations in 
SLC34A1 (OMIM*182309), leading to a syndrome of hypophosphatemia, 
osteoporosis and nephrolithiasis (116). Very recently, autosomal recessive mutations 
in SLC34A1 were shown to cause idiopathic infantile hypercalcemia (IIH) with 
hypophosphatemia and suppressed FGF23 levels (117). 
 
Other forms of hereditary hypophosphatemia with and without rickets 
KL-associated hypophosphatemia.  
As described in section 1.3.3 α-klotho is a co-receptor for FGF23 at the FGFR1c, and 
increased stimulation of this receptor leads to phosphaturia and hypophosphatemia. A 
balanced translocation between chromosomes 9 and 13 (t(9,13)(q21.13;q13.1)) of the 
KL gene (OMIM+604824), leading to up regulation of KL-transcription, has been 
found in the only described case of KL-associated hypophosphatemia (118). The 
patient was a 1-year old girl with poor linear growth, increasing head circumference, 
clinical and radiological signs of rickets, hypophosphatemia, renal phosphate wasting 
and elevated levels of parathyroid hormone and alkaline phosphatase. She also had 
dysmorphic features of the face, and an Arnold-Chiari 1 malformation (118). Dental 
involvement was not described.  
 
The α-klotho protein is considered an anti-aging hormone in mice (119). Accelerated 
aging has been observed in KL knockout mice, along with decreased insulin secretion 
and increased insulin sensitivity (120). Mice experimentally overexpressing KL have 
a prolonged life span (119). Human KL is expressed mainly in the kidney, and the 
secreted variant seems to dominate (121). Recent findings from mouse studies 
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suggest that α-klotho has endocrine, paracrine and autocrine effects independent of 
FGF23 (122).   
 
FGFR1c-associated hypophosphatemia – Osteoglophonic dysplasia 
Osteoglophonic dysplasia is a rare autosomal dominant condition caused by 
activating mutations in the FGFR1 gene (OMIM*136315) (123). The patients present 
with dwarfism, facial dysmorphism and sometimes craniosynostosis. It has also been 
associated with hypophosphatemia (124) and dental involvement, with failure of 
tooth eruption and mandibular malformations (123). As described in section 1.3.3 the 
FGFR1c, with α-klotho as co-receptor, is the functional receptor for FGF23 (58), and 
activating mutations in the FGFR1 gene leads to constitutive activation of the 
receptor and its intracellular tyrosine kinase domain. This has the same consequences 
as overexpression of FGF23.  
 
FGFR1-3 is implicated in skeletal development, and various mutations in the 
corresponding genes are responsible for a number of skeletal dysplastic syndromes 
(125).  In mice, the Fgfr4 has been shown to be a functional receptor for the group of 
endocrine FGFs, including FGF23 (126), but clinical significance of this association 
is not known, and there are no reports of human phosphate regulation disorders 
related to mutations in the FGFR4 gene.  
 
SLC9A3R1-associated hypophosphatemia 
Autosomal dominant mutations in the SLC9A3R1 gene (OMIM*604990) has been 
found in patients with nephrolithiasis associated with hypophosphatemia and reduced 
TmP/GFR, as well as osteoporosis or osteopenia (127, 128). The levels of 
1,25(OH)2D are elevated or in the upper normal range, while the FGF23 are normal 
or in the lower normal range (127, 128). SLC9A3R1 encodes the sodium/hydrogen 
exchanger regulatory factor 1 (NHERF1), which is involved in maintenance of the 
cytoskeleton of renal tubular cells and other polarized cells with microvilli (129), and 
in mice has been shown to be involved in intracellular trafficking and plasma 
membrane localization of the NaPi-IIa (130).  
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1.5.2 Treatment and follow up 
Treatment of hypophosphatemic rickets has evolved during the last 50 years. Initially 
high doses of vitamin D were used, with some improvement of rickets (7). In the 
seventies elemental phosphorus was added to the treatment, which improved growth, 
healing of rickets and reduction of bowing (131), but on the expense of 
nephrocalcinosis (132, 133) and hyperparathyroidism (131). 
 
Modern treatment still involves oral phosphate supplements combined with active 
vitamin D, as calcitriol or alfacalcidol, and recently updated treatment 
recommendations have been published (32, 134). The aim of the treatment is to 
improve rickets and growth while at the same time avoiding hypercalcuria and 
hyperparathyroidism. The daily dose of phosphate has to be split in several smaller 
doses given 4-6 times daily, as the serum level of phosphate is back to the low steady 
state within a few hours after administration. Each dose of phosphate gives a stimulus 
for increased secretion of PTH, both due to the peak in serum phosphate itself (131), 
as well as a transient decrease in serum calcium upon phosphate administration. This 
transient hyperparathyroidism is counteracted by active vitamin D, which is 
administered twice daily. Combination therapy is started once the diagnosis has been 
made, and that the starting dose of phosphate is low, to reduce gastrointestinal side 
effects, which can make compliance to treatment difficult. The doses of phosphate 
and vitamin D are then titrated up to the least efficient doses, i.e. the lowest 
phosphate dose that leads to healing of rickets, improved growth, and straightening of 
lower extremity axis deviation. The recommended doses (32), along with dosing 
interval and administration form, are given in Table 2. 
 
Combination therapy with phosphorus and calcitriol is recommended for all children 
with hypophosphatemic rickets (32, 135). In FGF23 dependent HH without rickets, 
treatment is not established. In FGF23 independent HR, as in HHRH, the production 
of 1,25(OH)2D is endogenously up-regulated, and thus only phosphorus supplement 
is  recommended. 
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Treatment continues until the child has reached final height and the growth plates are 
closed. Correcting osteotomy is performed if severe/disabling skeletal axis deviation 
persists when longitudinal growth is complete. Treatment in adults is not routinely 
recommended, but combination therapy is recommended as preparation for 
orthopedic surgery, after fractures and in cases of disabling bone pain (134).  
 
Table 2 Recommended treatment of hypophosphatemic rickets in children. 







 10 – 20 mg/kg/day  20 – 40 mg/kg/day  4 
Calcitriol1  Tablets  10 – 15 ng/kg/day  20 – 30 ng/kg/day  2 
Alphacalcidol1  Droplets Tablets  15 – 20 ng/kg/day  30 – 50 ng/kg/day  1 
1Active vitamin D is given as either calcitriol or alphacalcidol, and is recommended 
only for treatment of FGF23 dependent HR. Adapted from (32, 135). 
 
Close therapeutic monitoring is essential to ensure adequate treatment and therapeutic 
compliance, and to avoid development of complications. Recommendations for 
monitoring of HR are presented in Table 3 ((32). Clinical and biochemical controls 
are recommended at least four times annually, with extra biochemical controls after 
adjusting the doses of phosphate of vitamin D. Skeletal X-rays of the wrist and lower 
extremities are performed every 2 years to ensure healing of rickets (32).  
 
Normalization of growth rate and clinical and radiological healing of rickets are 
indicators of sufficient phosphorus supplementation. Serum phosphorus level is not a 
good indicator of treatment efficiency, but is used as a guidance to determine least 
efficient dose. This can be tested in a phosphate challenging test: Serum phosphate is 
measured in the fasting state in the morning, immediately before administration of 
phosphorus, and then every 30 minutes for 150 minutes after administration of the 
child’s regular dose. The peak S-phosphate is recommended to reach lower reference  
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Table 3 Therapeutic monitoring of hypophosphatemic rickets 






Skeletal pain  
Normal growth 
Heal rickets 
No axis deviation 




and calcitriol doses 
Dental 
















 Every 3 months  
High ALP: increase 
phosphate- and 
calcitriol doses. 
























Healing of rickets 
Normal growth 
 Every 2 years  
Increase phosphate- 






and calcitriol dose 
1Based on recommendations in (32) 
1S-P is not used in therapeutic monitoring, except as part of the phosphate 
challenge test. 
2S-P is measured in the fasting state, immediately before administration of the 
child’s regular morning dose of phosphate, and then every 30 minutes for 150 
minutes. The peak S-P is recommended to reach lower reference interval, and the 
difference in S-P between pre and post administration (delta S-P) is recommended 
to be about 0.5 mmol/L (6).  
 
interval, and the difference in S-phosphate between pre and post administration is 
recommended to be about 0.5 mmol/L (6). This ensures a peak S-phosphate level 
sufficient for proper mineralization of bone, while at the same time reducing 
phosphate elicited PTH secretion. Monitoring for hypercalcuria and nephrocalcinosis 
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is effectuated by checking for hypercalcuria at every clinical visit. The U-Ca/Crea-
ratio should be less than 0.87 mmol/mmol. Renal ultrasonography is performed every 
2-5 years (136). As discussed above, the mildest degrees of nephrocalcinosis may not 
be of clinical significance, and if stable, vitamin D doses can be kept unchanged. 
However, if hypercalcuria increases or the ultrasonography shows increasing 
nephrocalcinosis, vitamin D doses should be reduced to avoid compromising renal 
function.  
 
Elevated levels of PTH can be counteracted by reducing phosphorus dose, or if this 
worsens growth and rickets, by increasing the calcitriol dose. Urine 
calcium/creatinine ratio is measured to avoid hypercalcuria and risk of 
nephrocalcinosis. In this case, calcitriol dose must be lowered. In difficult cases of 
secondary hyperparathyroidism, where increase in calcitriol dose can not be done, the 
calcimimetic drug cinacalcet can be added to treatment (137).  
 
1.6 Hereditary hyperphosphatemia 
Hereditary hyperphosphatemia refers to two closely related conditions caused by 
reduced function of FGF23, namely hyperphosphatemic familial tumoral calcinosis 
(HFTC) and hyperphosphatemic hyperostosis syndrome (HHS). The clinical and 
biochemical phenotype in these conditions mirrors the phenotypes of hereditary 
hypophosphatemia.  
 
1.6.1 Genetics in hereditary hyperphosphatemia 
Mutations in three genes, GALNT3, FGF23 and KL, have been associated with HFTC 




Homozygous and compound heterozygous mutations in the GALNT3 gene (OMIM 
*601756) were the first to be associated with HFTC (138) and HHS (139), and 
mutations in the first nine of all 10 exons have been described (140). GALNT3 
encodes the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase3 
(GalNAcT3) responsible for O-glycosylation serine and threonine residues of FGF23, 
making FGF23 less susceptible to proteolysis by furin proteases (141). Inactivating 




While mutations affecting the cleavage site in exon 3 stabilizes the FGF23 protein (se 
earlier section), homozygous or compound heterozygous mutations in other parts of 
the FGF23 gene will destabilize FGF23 (143) and lead to increased proteolysis by the 
furin protease. Mutations associated with HFTC/HHS probably disturb the O-
glycosylation of FGF23 by GalNAcT3 (142). 
 
KL 
As described earlier, because of the low receptor affinity of FGF23, α-klotho is an 
obligate co-receptor for the binding of FGF23 to its receptor, FGFR1. An inactivating 
mutation in KL has been described only once, in a severe case of HFTC (144). 
 
1.6.2 Clinical features in hereditary hyperphosphatemia 
Hyperphosphatemic familial tumoral calcinosis 
HFTC was first described by Giard in 1898 (145), and usually presents as 
symptomatic soft tissue calcifications in proximity to large joints such as the hip or 
shoulder girdle. The tumors can increase in size to inhibit joint movement, or make 
overlying skin rupture, with emptying of a white matter composed of calcium-
phosphate crystals. In addition there are reports of conjunctival and retinal 
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calcifications (146, 147), testicular microlithiasis (148), and vascular calcifications 
(149). Dental involvement, with short dental roots, obliterated pulp chambers and 
enamel defects, has also been described (150, 151). Biochemically, there is 
hyperphosphatemia with an increased TmP/GFR, as well as high normal or increased 
levels of 1,25(OH)2D (152, 153), while serum calcium and PTH are usually in the 
normal range(148, 154). The combination of low serum or plasma levels of intact 
FGF23 and increased levels of c-terminal FGF23 is characteristic (155).  
 
KL-associated hyperphosphatemia has been described only once, in a 13-year-old girl 
with severe soft tissue- and vascular calcifications. She had hypophosphaturic 
hyperphosphatemia, but also hypercalcemia, hyperparathyroidism and elevated levels 
of FGF23. Except for vascular calcifications, there were no signs of accelerated aging 
(144). 
 
Hyperphosphatemic hyperostosis syndrome 
Hyperphosphatemic hyperostosis syndrome was described by Melhem in 1970, as 
recurrent episodes of spontaneous painful swelling of limbs (156). Each episode 
affected one limb and was accompanied by fever and elevated blood sedimentation 
rate in the acute phase. The swellings disappeared without treatment during weeks to 
months. Skeletal x-ray shows areas of cortical hyperostosis with onionskin 
appearance and periosteal apposition corresponding to the swellings, and important 
clinical and radiological differential diagnoses are osteomyelitis and osteosarcoma. 
This phenotype has been described in children and young adults (139).  
 
1.6.3 Treatment and follow-up 
Treatment of HFTC is difficult and only partially successful. Different therapeutic 
approaches to reduce intestinal phosphate absorption and renal phosphate 
reabsorption are normally conducted, with limited success (157). Combination 
therapy with oral phosphate binders and acetazolamide, a carbonic anhydrase 
inhibitor, has been reported to lower serum phosphorus levels and reduce tumoral 
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masses in some patients (158). Surgical intervention with extirpation of the calcific 
tumors is rarely successful, as the tumors tend to recur at the site of surgery, 
sometimes with development of chronic fistulation. Future therapeutic possibilities 
may include direct targeting of blood FGF23 levels. 
 
1.6.4 Complications and prognosis 
HFTC/HHS is a chronic condition, and as stated above, treatment is only partially 
successful. Vascular calcifications as seen in our patient, and also described in the 
literature, points to a possible risk of premature cardiovascular disease. However, this 
has not been systematically examined, and the long-term prognosis and life 
expectancy for this condition is not known. 
 
1.7 Aquired disorders with elevated FGF23  
Tumor induced osteomalacia 
Tumor induced osteomalacia (TIO) is a rare paraneoplastic phenomenon associated 
with mesenchymal tumors (159), and recently tumors causing TIO has been accepted 
as a formal tumor entity called Phosphaturic mesenchymal tumor (PMT) (160). This 
acquired form of osteomalacia was first described by McCane in 1947 (161), but it 
was not until 12 years later that the association to bone tumors was found (162). The 
patients have hypophosphatemia and reduced TmP/GFR caused by tumor production 
of FGF23. PMT is very rare in childhood (159), and will cause a clinical and 
biochemical phenotype similar to XLHR, ARHR and ADHR in growing children. A 
search for a tumor causing TIO might be considered in a child with relatively abrupt 
onset hypophosphatemia with reduced TmP/GFR, a low or low normal 1,25(OH)2D, 
with a negative family history and mutation screening of PHEX, FGF23, DMP1, 
ENPP1 and FAM20C has failed to identify any pathogenic mutation (163). However, 
the FGF23 producing tumors are often small and difficult to identify, and there is 
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often a diagnostic delay (164). Definite treatment of TIO is by complete removal of 
the tumor, but if the tumor cannot be localized, or is not available for surgery, the 
treatment is principally the same as in HR (163).  
 
Chronic renal failure 
Chronic renal failure (CRF) is another acquired condition associated with elevated 
levels of FGF23 (165, 166). The mechanism behind elevated FGF23 in CRF is not 
fully clarified; while the hyperphosphatemia of CRF will give a stimulus for 
increased production of FGF23, increased levels of FGF23 are found even before the 
development of hyperparathyroidism and hyperphosphatemia in CRF (166, 167). 
Furthermore FGF23 levels rise gradually corresponding to the decline in kidney 
function (168). Normally, most of the phosphate-regulating properties of FGF23 are 
dependent on α-klotho as a cofactor for FGFR1. In CRF the production of α-klotho 
from the distal kidney tubule is reduced (169), and this has been suggested as a 
mechanism for a compensatory over-production of FGF23 from bone (170). 
Hyperphosphatemia itself is associated with cardiovascular calcifications. In addition, 
the elevated levels of FGF23 are thought to have independent pathologic effects. 
Pathologically elevated levels of FGF23 have been associated with left ventricular 
hypertrophy (171, 172), endothelial dysfunction (173), atherosclerosis (174), 
retinopathy (175) and increased risk of mortality in chronic kidney disease (168) and 
persons with coronary heart disease (176). 
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2. Aims  
The overall aim of this thesis was to study familial disorders of phosphate 
metabolism. 
 
Specifically, we used data and samples from Norwegian patients to:  
• Study the prevalence of hereditary hypophosphatemia in the Norwegian 
pediatric population. 
 
• Study the phenotype and outcome of Norwegian children with hereditary 
hypophosphatemia. 
 
• Study the genetic causes in Norwegian families with hypo- or 
hyperphosphatemia 
 




3. Materials and methods 
3.1 Patient population 
During 2009 all pediatric hospital departments in Norway were contacted to identify 
children with hypophosphatemic rickets. In addition, we retrieved anonymized data 
from the Norwegian Patient Registry (NPR), where all diagnosis codes from all 
national health institutions are linked to the personal identification number in the 
Norwegian Central Office of Civil Registration. NPR data was used to match the 
number of cases identified at the hospital departments with the number of patients 
younger than 18 years registered with the diagnosis code “E83.3 Disorders of 
phosphorus metabolism and phosphatases”, in the World Health Organization’s 
International Classification of Diseases version 10 (WHO ICD-10). Because the NPR 
data were anonymized, we were not able to identify cases, only the number of 
patients. 
 
By contacting the hospital departments, we were able to identify 23 children 
diagnosed with hypophosphatemic rickets by December 31. 2009. The number of 
children in the National Patient Registry with the ICD-10 diagnosis “E83.3 Disorders 
of phosphate metabolism and phosphatases” were 32 by the end of 2009. All hospital 
departments were therefore contacted again, to clarify the diagnosis of the nine cases 
not reported on the first personal contact. Four of the patients had hypophosphatasia, 
and five had transient hypophosphatemia in the course of malignancy, premature 
birth, or other underlying condition. We identified another four patients during the 
period January 01 2010 until December 31 2013, two of which were immigrants 
during this period, one patient born to a XLHR mother, and one child born 2008 but 
not diagnosed until 2010. Despite repeated contact with the treating physician, one 
male patient with hereditary hypophosphatemia could not be included in the study. In 
addition, for two patients we were not able to review the patients’ medical records.  
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The patients were informed about and recruited to the study by the treating physician. 
A total of 28 hypophosphatemic patients gave written informed consent (Figure 7). 
Through contact with the hospitals, we also identified, and got the informed consent, 
from three adult patients with hyperphosphatemic tumoral calcinosis. 
 
In cases where a genetic diagnosis could not be established with standard genetic 
analysis, also healthy family members of the index cases were included in the project. 
The diagnostic criteria for hereditary hypophosphatemia were hypophosphatemia 
combined with reduced TmP/GFR, normal serum calcium level, inappropriately 
normal or decreased levels of 1,25(OH)2D, elevated alkaline phosphatase and normal 
or slightly elevated PTH (134). A family history or genetic diagnose was supportive, 
but not required for the diagnosis. We did not include patients with Fanconi 
syndrome or other tubulopathy, patients with vitamin D dependent rickets, tumor 
induced osteomalacia or vitamin D deficiency. Nor did we include patients with 
transient hypophosphatemia secondary to acute illness. 
 
The diagnostic criteria for hyperphosphatemic tumoral calcinosis and 
hyperphosphatemic hyperostosis syndrome were a history of tumoral calcinosis or 
diaphysitis in patients with hyperphosphatemia combined with a high normal or 
elevated TmP/GFR (156, 177). We did not include patients with hyperphosphatemia 
and calcifications due to kidney failure, hypoparathyroidism and 
pseudohypoparathyroidism. 
 
3.2 Review of medical history 
The medical records of included patients were reviewed, and all data relevant for the 
phosphate balance disorder were recorded, including age at diagnosis, clinical and 
biochemical findings at diagnosis, treatment history and development of 
complications. Laboratory data from each visit from the time of diagnosis to the time 
of inclusion in the study, including serum levels of calcium, phosphorus, alkaline 
phosphatase, creatinine, parathyroid hormone and vitamin D status (25OHD and 
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1,25(OH)2D) were also recorded, as well as results from kidney ultrasound and 
skeletal x-ray examinations.  
 
3.3 Genetic analysis 
For the purpose of genetic analyses and biobanking, in all included subjects genomic 
DNA was purified from blood using the QiaSymphony system (Qiagen, Hilden, 
Germany).  
 
If mutation status was not already known, all exons and intron-exon boundaries of 
PHEX were sequenced in the index case of each family. If a disease causing mutation 
was not found, and the inheritance pattern suggested a sporadic case or X-linked 
dominant disease, we sent DNA for multiplex ligand-dependent probe amplification 
(MLPA) analysis of PHEX at the Molecular Genetics Laboratory, Royal Devon and 
Exeter Foundation NHS Trust, Exeter, Devon, UK. The PHEX MLPA analysis can 
identify mid-size deletions and insertions not detected by regular Sanger sequencing 
or chromosomal analysis.  
 
In addition to PHEX analysis, we sequenced all exons and intron-exon boundaries of 
FGF23, DMP1, KL and ENPP1 in successive order, in subjects without pathogenic 
PHEX mutations. After the identification of FAM20C mutations after whole exome 
sequencing in two siblings with hypophosphatemia, hyperphosphaturia, dental 
abscesses and osteosclerosis (178), we also screened FAM20C in patients without 
mutations in the aforementioned genes. In patients with hyperphosphatemic tumoral 
calcinosis we screened all exons and intron-exon boundaries of FGF23, GALNT3 and 
KL. 
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3.3.1 Sanger sequencing  
In short, DNA targets were first amplified by polymerase chain reaction (PCR) (list 
of primers available upon request) using the AmpliTaq Gold ® DNA polymerase 
system (Applied biosystems, Life biosystems, Carlsbad, California, USA. PCR 
amplicons were purified with 2 µl of ExoSapIT®. Using the Big Dye Terminator ® 
chemistry sequencing was performed on the 3730 DNA analyzer, (Applied 
biosystems) and analyzed using the SeqScape ® software (Applied biosystems).  
 
3.3.2 Further genetic analyses 
In subjects without a genetic diagnose after screening of the genes known to cause 
hypophosphatemic rickets, further genetic analysis was considered if this was 
anticipated to have clinical and therapeutical relevance. Whole genome SNP 
genotyping was conducted if the pedigree was considered informative for this 
purpose. Whole exome sequencing was conducted after the patients had received 
genetic counseling and given specific written informed consent concerning whole 
exome sequencing. Genomic DNA was purified from blood using the QiaSymphony 
system (Qiagen, Hilden, Germany). Whole genome SNP genotyping was performed 
with GeneChip Human Mapping 6.0 array (Affymetrix, Santa Clara, USA). Whole 
Exome capture using Roche-Nimblegen's SeqCap EZ Exome v2 and sequencing on 
the Illumina HiSeq was performed at the HudsonAlpha Institute for Biotechnology 
(Huntsville, AL) to a median coverage of 154x according to manufacturer's 
protocol(179).  The paired-end 100nt reads were analyzed with CASAVA v1.8 
(Illumina Inc) followed by alignment with BurrowS-Wheeler transformation(180). 
PCR duplicates were removed with PICARD (http://picard.sourceforge.net) and the 
Genome analysis toolkit (GATK) was used for base quality recalibration(139). SNPs 
and indels were called using the GATK unified genotyper using a minimum threshold 
of 8X sequencing depth and quality score ≥ 30. Annovar (181) and in-house scripts 




The prevalence of hypophosphatemic rickets was calculated based on the number of 
patients aged 0-17 years with this diagnose in 2009 and the total number of people in 
Norway aged 0-17 years by January 1.2010, obtained from the official Statistics 
Norway database (182). In the XLHR patients, we compared phenotypic, treatment 
and complication data in male versus female subjects. According to an earlier study 
(83), the XLHR patients were grouped depending on initiation of treatment before or 
after one year of age, and phenotypic and complication data were compared for these 
groups. Between-group comparisons of medians were performed using the 
independent samples Mann-Whitney U-test, and comparisons of proportions were 
performed with Fisher’s exact test. 
 
3.5 Ethics and approvals 
Written informed consent was obtained from all study participants. The project was 
conducted according to the declaration of Helsinki and was approved by the Regional 
Committee for Medical and Health Research Ethics, Region West, Norway (REK 
number 2009/1140). The study was registered at www.ClinicalTrials.gov with 
registration number: NCT01057186. In cases where exome sequencing were offered, 
the patients received genetic counseling by a registered genic counselor before giving 
a specific written informed consent, and also after the results were ready, in 
concordance with the Norwegian Biotechnology Act (183). Children that were 
recruited before the age of 16 years, and who turned 16 years during the time of the 
ongoing study and biobanking, gave a new, written informed consent at the age of 16 




4.1.1 Overview of papers I-III 
Paper I describes the cohort of Norwegian children with HH. This paper is the first 
to describe a complete national cohort of HH, including XLHR, and we show that the 
prevalence of XLHR in Norway is 1 in 60.000, as compared to the commonly 
reported international prevalence of 1 in 20.000 (71, 72). PHEX mutations were 
confirmed in 21 of the 28 included patients (Figure 8) from 13 different pedigrees, 
and nine of the 13 PHEX mutations were novel. In the non-XLHR patients we 
identified novel compound heterozygous mutations in FAM20C in two male siblings 
(Paper II), and novel compound heterozygous mutations in SLC34A3 in a male with 
HH with hypercalcuria. In four of the children we could not identify the pathogenic 
mutation.  
 
The median age for diagnosis of HH was 2.1 years and for XLHR 0.9 years, and 
treatment with oral phosphate and active vitamin D was started shortly after diagnosis 
in most. In XLHR patient we compared phenotypes based on gender and on treatment 
start before or after one year of age. Although none of our comparisons reached 
statistical significance, we were able to show trends, including a tendency for males 
being more growth restricted and more often have dental involvement than females. 
We found no effect on growth by early start of treatment, but early start of treatment 
and higher doses of phosphate supplement tended to be associated with a risk for the 
development of nephrocalcinosis.  
 
Paper II describes the identification of a novel FGF23 dependent form of hereditary 
hypophosphatemia, associated with mutations in the FAM20C gene. Two male 
siblings with hypophosphatemia, hyperphosphaturia, severe dental complications, but 
with normal growth and no signs of rickets, also showed intracerebral calcifications 
and mild dysmorphic features. Exome sequencing revealed novel compound 




Figure 7 Inclusion of patients 
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heterozygous for the wild type allele, were unaffected. Mutations in FAM20C has 
earlier been associated with lethal and non-lethal variants of Raine syndrome, but we 
show for the first time, that the hypophosphatemia seen in many of these subjects is 
associated with inappropriately elevated levels of FGF23. 
 
Paper III describes two adult siblings with hereditary hyperphosphatemia, and a 
phenotype of HFTC in the male and a combined phenotype of HFTC and HHS in the 
female. We identified a novel homozygous mutation in the GALNT3 gene, and 
pedigree analysis revealed consanguinity, as the parents had a common ancestor eight 
generations back. They were diagnosed and started treatment at the ages of 37 and 50 
years, respectively. In retrospect, they both had symptoms of disease in childhood 
and adolescence. The paper describes the natural evolvement of the disease, with long 
symptom free intervals, and also describes novel phenotypic features and great 
phenotypic variability between the siblings. Finally, the paper reviews all 54 
published cases of HFTC and HHS in which the pathogenic mutation had been 
identified, and shows that a combined phenotype of HFTC and HHS is more common 




5.1 Methodological issues 
5.1.1 Study design 
The retrospective design of the study implies that registration of clinical data for 
children treated by different clinicians in different hospitals may show some 
variations. Furthermore, biochemical analysis has been performed in different 
hospital laboratories, and may thus have slight differences in reference intervals, 
despite use of equal methods and equipment throughout Norway. 
 
In XLHR we wanted to explore the possible associations between gender, mutation 
type, age at start of treatment, and different phenotypic features. However the sample 
size was rather small, with only 21 patients, and several of these were first or second 
degree relatives. In some of the pedigrees, all the affected children were females, 
whereas in other families there were only males. Thus, when comparing the effect of 
gender on phenotype or genotype-phenotype associations, it is not possible to know 
whether it is gender or genotype that is most influential on phenotype. In three 
families, there were affected children of both genders, four females and three males. 
However, one of these families was immigrant, and the children were diagnosed very 
late, and we have no information on past medical history. Thus, with only three 
females and two males eligible for comparison, there would still be problems with the 
validity of the results of statistical analysis. Also, we have no information about 
treatment compliance that would be relevant for the data collected at the last 
registered consultation.  
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5.1.2 Ethical considerations in genetic analyses 
In four patients, we were not able to find the genetic diagnose, despite extended 
genetic analyses. In two of these families we have proceeded with exome sequencing, 
but without finding a plausible candidate gene in either family.  
 
Exome sequencing carries the risk of accidentally finding pathogenic mutations in 
genes associated with potentially serious diseases, but not subject of the current 
research. Therefore, if exome sequence was considered, patients were referred for 
genetic counseling at an approved hospital department before deciding to give 
consent for exome sequencing, and also after the results were ready. This is in line 
with the Norwegian Biotechnology Act, which regulates the use of genetic testing of 
children and adults. 
 
5.2 Discussion of results 
5.2.1 Hereditary hypophosphatemia in Norwegian children – Paper 
I 
Prevalence of hereditary hypophosphatemia and hypophosphatemic 
rickets in Norway 
We found a prevalence of XLHR of 1 in 60.000 Norwegian children. There are not 
many studies reporting the prevalence of XLHR in the population described; actually 
until recently, there is one commonly cited paper, reporting a prevalence of 1 in 
20.000 (71). This number was recently confirmed by a study from the population of 
Southern Denmark (72). However, both these studies are regional, and the risk of 
selection bias cannot be ruled out. Another possible explanation of the lower 
prevalence of XLHR observed in our cohort might be sex-dependent differences in 
disease penetrance; Earlier studies of large pedigrees of XLHR patients found a lower 
penetrance of skeletal manifestations in hypophosphatemic females as compared to 
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full penetrance of skeletal manifestations in hypophosphatemic males (184, 185). It is 
thus possible that, in Norwegian families without affected males, there are 
undiagnosed hypophosphatemic females. In X-linked dominant disorders, the 
expected ratio of affected females to males is 2:1, whereas in our population the 
female to male ratio was 16 to 5, or 3:1. Hence, this does not support a theory of a 
large proportion of undiagnosed Norwegian XLHR females. Our study included only 
children already in contact with health care because of hereditary hypophosphatemia, 
and in most instances serum phosphorus had been measured in apparently healthy 
parents and siblings. Mutation screening of the PHEX gene in all first-degree 
relatives of the XLHR probands, even if they are symptom free and 
normophosphatemic could theoretically detect subclinical XLHR, but this raises 
difficult ethical considerations of predictive genetic testing, for which strict 
guidelines apply (183). Children with hypophosphatemic rickets were identified 
through direct contact with treating physicians at all pediatric hospital departments in 
Norway, and compared to data from the Norwegian Patient Registry (NPR), as 
described in Paper I. We did not contact general practitioners in the search for 
children with hereditary hypophosphatemia, and therefore cannot rule out the 
possibility of hereditary hypophosphatemia in asymptomatic children.  
 
The true prevalence of XLHR in the Norwegian pediatric population might be higher 
than our study shows, but the prevalence of clinical significant XLHR is probably 
correctly reported in our study. 
 
Genetics in hereditary hypophosphatemia 
PHEX mutations were confirmed in 21 of the 28 included patients (Figure 8) from 13 
different pedigrees, and comprised 87 % of the verified mutations. This supports 
recent reports from other cohorts (97), and confirms that XLHR is the most common 
variant of HR. Nine of the 13 PHEX mutations (69 %) were novel, not previously 
reported in the literature or found by searching the SNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/index.html), PHEX database 
(http://www.pahdb.mcgill.ca/cgi-
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bin/phexdb/phexdb_mutQ1.cgi?field=ID_mut&value=) or the ExAC Browser 
(http://exac.broadinstitute.org/gene/ENSG00000102174). Our finding supports what 
has earlier been reported, that a high proportion of the mutations in this gene are 
unique to each pedigree (185). In the non-XLHR patients we identified novel 
compound heterozygous mutations in FAM20C in two male siblings, and novel 
compound heterozygous mutations in SLC34A3 in a male with HH with 
hypercalcuria, while no likely pathogenic mutations were found in the FGF23, 
DMP1, ENPP1 and KL genes. Although we could not identify the pathogenic 
mutation in four of the children, the mutation detection rate (24 of 28 included 
patients) is in line with recent reported cohorts of hypophosphatemic rickets (97, 
186).  
 
We identified one adolescent male with compound heterozygous mutations in the 
SLC34A3 gene, suggestive of HHRH, but without any signs of rickets or other 
mineralization disorders. He had hypophosphatemia combined with a reduced 
TmP/GFR and hypercalcuria, detected during diagnostic work-up for recurrent 
kidney stones. He had a novel splice mutation in intron 7, affecting a conserved splice 
donor site and a previously reported intronic deletion mutation, (111). The lack of 
skeletal involvement is not unique in our case. Recent studies have shown that renal 
calcification was the only clinical manifestation of SLC34A3 mutations in about 10 % 
of homozygous and 16 % of compound heterozygous carriers (187, 188). The 
phenotypic and genotypic diversity in conditions associated with SLC34A3 mutation 
reported by others, is thus confirmed by our findings.  
 
In four of the included patients, from four different pedigrees, we were not able to 
identify the likely pathogenic mutation by standard Sanger sequencing. However, as 
illustrated by our finding of FAM20C mutations, exome sequencing can sometimes 
help reveal novel associations between genotype and phenotype. In search for novel 
mutations in genes associated with pathways involving FGF23, phosphate 
reabsorption and tissue mineralization, we proceeded with exome sequencing in two 
of the patients without a genetic diagnosis, but without identifying any obvious 
 55 
candidate genes likely to explain disease in either patient. This illustrates the 
limitations of exome sequencing in families with only one or two affected subjects. 
Although this method is currently becoming more efficient, more commonly 
available and cheaper, the challenges remain in processing of output files. After 
filtering against databases with common genetic variants, the list of genetic variants 
potentially associated with the disease in question includes almost 200 genes in an 
autosomal dominant model, 0-2 genes in a de novo-dominant model and 5-30 genes 
in a recessive model. Detailed knowledge on the physiological mechanisms and 
pathways is essential to reduce this list of candidate genes, but often the search for the 
likely disease-causing mutation ends without results. In addition, exome sequencing 
screens only the coding part of the human genome, while the non-coding parts of the 
genome includes important gene regulatory elements. Mutations in such elements has 
also been associated with disease, but would not be detected in exome sequencing. 
Whole genome sequencing on the other hand, is becoming feasible in terms of costs 
and would enable detection of non-coding and more complex genetic re-
arrangements. This would however, come at the expense of increased complexity, 
and being more computationally demanding and yielding large numbers of rare 
potential candidate variants from which it is no trivial quest to prioritize for further 
studies.  
 
On the other hand, as illustrated by our finding of novel mutations in FAM20C (178), 
exome sequencing can give results that have implications for current understanding 
of pathophysiology and disease. Our finding of an association between FAM20C 
mutations and elevated levels of FGF23, confirmed findings in murine Fam20c KO 
models, and has been important for later research defining the role of FAM20C in 
phosphate- and mineralization homeostasis (se section 5.2.2).  
 
Mineralization defects and growth in XLHR 
Clinical or radiological signs of rickets or skeletal axis deviation were found in all 
children with XLHR, including seven children diagnosed before the age of one year 
through family screening, and starting treatment before development of symptoms. 
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Early start of treatment and adequate doses of phosphate did not seem to prevent 
growth restriction or persisting skeletal axis deviation at the last registered 
consultation.  
 
Growth was complete in six of 21 patients at the last registered consultation, and two 
of these, both males, had correcting osteotomy after longitudinal growth had 
completed, while in two females and one male, the axis deviation had not persisted 
(data missing for one female). One of the males needing correcting osteotomy was 
immigrant to Norway at age 15.5 years, and had not received any medical treatment 
for his condition before this. The other male with persisting axis deviation after 
cessation of growth, had been treated with adequate doses of phosphate (mean 32 
mg/kg/day) and alphacalcidol (mean 54 ng/kg/day) from the age of 6 months. The 
two female patients without axis deviation had received phosphate doses above the 
recommended range (mean 61 and 74 mg/kg/day) and had signs of nephrocalcinosis 
on renal ultrasound, while the male without axis deviation had received an adequate 
phosphate dose (mean 39 mg/kg/day) and had no signs of nephrocalcinosis. This 
indicates a trend for more aggressive treatment in the patients without persisting axis 
deviation, but with an increased risk of nephrocalcinosis. 
 
There was a trend for a higher proportion of dental involvement in males (4 of 5) than 
females (5 of 15), and also a trend for less dental involvement in children who started 
treatment before the age of one year. These findings support previous reports of more 
severe dental phenotype in post pubertal males than females (189, 190), and 
observations that dental involvement can, to some extent, be prevented by starting 
treatment before one year of age, suggesting the importance of proper mineralization 
of dentin prior to the eruption of teeth (191). 
 
Without treatment, hypophosphatemic rickets is associated with short stature, both 
because of skeletal axis deviation in the lower extremities, but also because of poor 
linear growth (84). In our material the two immigrant children with XLHR, who had 
not received medical treatment until the ages of 6.5 and 15.5 years, and had height z-
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scores of -6.5 and -5.1, respectively, exemplify this. Treatment with phosphate and 
active vitamin D will correct axis deviation and facilitate growth, but most often the 
correction is not complete. In our material, if excluding the two immigrant children 
and one with missing data, 16 of 18 patients had negative height z-score at the last 
registered consultation, and in five of 18 the height z-score was -2 or lower, despite 
treatment with adequate doses of phosphate and alphacalcidol. While some studies 
argument for a positive effect on linear growth by starting treatment before the age of 
one year (83, 192), we did not find trends for this in our cohort; early start of 
treatment was associated with both positive and negative change of the height z-
score, while in children who started treatment after one year of age, this change was 
less pronounced. This probably reflect that height z-score at birth reflects to a large 
extent the intrauterine conditions for growth, and change during the first year of life 
z-score depending on the genetic growth potential and postnatal environment, also in 
healthy children (193). 
 
Gender, genotype and phenotype in XLHR 
As discussed above, persistent bowing, dental involvement as well as growth 
restriction tended to be more prevalent in males than females. Studies have shown 
that both hypophosphatemia (194, 195) and skeletal manifestations (196) seem more 
pronounced in males, and that some XLHR females may actually show only slight 
hypophosphatemia and no, or only a very mild, skeletal phenotype (195, 197). 
Conversely, some studies report no difference in skeletal phenotype between males 
and females (189, 198). Recent reports suggest that estrogen, which plays an 
important role in skeletal health, stimulate the production of FGF23 in bone, and 
estrogen therapy is associated with increased bone mineral density, as well as reduced 
serum levels of phosphate, PTH and calcitriol, probably via increased levels of 
FGF23 (199, 200). It has also been shown that estrogen therapy down-regulates the 
kidney proximal tubule type IIa sodium phosphate cotransporter in rats (201). These 
findings support the observations made in ADHR, where in some females the disease 
become clinically evident after puberty or in pregnancy (108), as estrogen levels are 
increasing. However, this cannot explain a milder phenotype in XLHR females, and 
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the influence of estrogen on FGF23 production in states of FGF23 dysregulation, 
needs further clarification. 
 
In line with an earlier study (186), the patients were grouped according to the effect 
of the PHEX mutation being either highly likely complete loss-of-function variants, 
i.e. non-sense mutations and mutations resulting in a truncated protein, or likely to 
reduce protein function, i.e. missense mutations. When comparing height z-scores, 
prevalences of rickets and bowing, and the prevalence of dental involvement, we did 
not find any differences between the two groups, and this supports what was found in 
a recent study (186). Other studies have found a more severe skeletal phenotype in 
patients with truncating mutations (202-204). However, observations from our cohort, 
confirming reports from others (189, 205), show that even in patients from the same 
family and thus carrying the same mutation, the skeletal phenotype can be very 
different. What individual factors responsible for this diversity in growth and bone 
mineralization is not fully clarified, but it could be due both to modifying genetic 
variants elsewhere in the genome, epigenetic or environmental factors. Recent reports 
have shown associations between the FGF23 sequence variant c.C716T (p.T239M, 
rs7955866) and lower levels of serum phosphate and lower renal tubular maximum 
reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) (206), and 
lower plasma intact PTH in healthy children and adults (207). In neither of these 
studies, the levels of serum intact FGF23 were higher in individuals homozygous or 
heterozygous for the c.C716T variant as compared to individuals with only the wild-
type allele, and this points to a possible functional importance of this variant. There 
are several monogenic of phosphate balance disorders described, but probably many 
yet unidentified allelic variants influencing phosphate metabolism and bone 
mineralization, collectively accounting for the phenotypic heterogenesity of these 
disorders. 
 
Treatment and complications in hypophosphatemic rickets 
Twenty-six of 28 included patients had been treated with phosphate and calcitriol 
during childhood. The two patients not treated had not been diagnosed until the 
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inclusion in the study, and therefore treatment had not yet started. Detailed treatment 
data was available for most of the patients, and these are presented in appendix Table 
5 and 6 of the Appendix. 
 
Nephrocalcinosis is a very prevalent complication of phosphate treatment in HR, and 
treatment is monitored and adjusted in order to avoid this complication. In our 
material, nine of the 21 XLHR patients developed nephrocalcinosis. However, of the 
12 patients without nephrocalcinosis, only four had been treated with phosphate and 
vitamin D for a sufficient period of time for nephrocalcinosis to develop. We set this 
cut off to 5 years, as the nephrocalcinosis was detected within five years of start of 
treatment in all children with this complication. Unfortunately, nephrocalcinosis was 
not graded according to recommended classification in all patients, and thus we were 
not able further classify the severity of nephrocalcinosis. However, renal function 
was retained in all patients with nephrocalcinosis, except in one female XLHR patient 
with high-grade nephrocalcinosis, who also developed tertiary hyperparathyroidism 
(see below) (208). She had transient, mild deterioration in renal function that 
responded well to adjustment of treatment. This points to an important consideration 
for the therapeutic management of nephrocalcinosis: Nephrocalcinosis is quite 
common in phosphate- and vitamin D treated HR patients, with reported prevalences 
of 33 to 80 % (83, 132, 133, 192, 209-213), and is not seen in patients not treated 
with phosphate (209, 211, 212). However, it is mostly mild, and rarely leads to renal 
failure (211). This raises the question of the clinical relevance of mild 
nephrocalcinosis in HR children who are phosphate dependent to assure growth and 
healing of rickets. This is also reflected in recently published treatment guidelines (se 
below); earlier a calcium/creatinine ratio < 0.6 mmol/mmol has been considered safe 
considering the risk of nephrocalcinosis. Current guidelines consider a 
calcium/creatinine ratio < 0.87 mmol/mmol as within the safety range (32). 
 
Elevated levels of PTH was found in all the patients in our cohort at some point 
during treatment, supporting that secondary hyperparathyroidism (HPT) is a common 
complication to phosphate treatment in HR, explained by the small surges in serum 
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phosphate following each dose of phosphate, triggers increased production and 
release of PTH (131). Secondary HPT is also a well-known complication in other 
conditions of chronic hyperphosphatemia, as for instance chronic renal failure (CRF) 
(214), while in healthy individuals, hypophosphatemia leads to reduced PTH-levels 
through an increase in 1,25(OH)2D (215). However, in HR and CRF, the elevated 
level of FGF23 inhibits production of 1,25(OH)2D. More interesting, however, is the 
observation that 10 of 15 XLHR children had PTH levels above the upper age 
appropriate reference range already before the start of treatment, supporting earlier 
reports of PTH levels often being slightly elevated in HR patients also before the start 
of phosphate treatment (87-89). There are evidence suggesting an inhibitory effect of 
FGF23 on PTH production (216), but as FGF23 levels are elevated in FGF23 
dependent HR, the mechanism behind elevated PTH in HR becomes even more 
difficult to understand. Thus, the inappropriate PTH response in untreated HR, and 
the interplay between phosphate, FGF23 and PTH, still need to be explored. 
 
In our cohort, two patients developed tertiary HPT, which is a complication of long 
standing secondary HPT, where the parathyroid glands become autonomous and do 
not respond appropriately to negative feedback aiming to reduce PTH production and 
secretion. A female XLHR patient, had received relatively high doses of phosphate 
and relatively low doses of calcitriol for more than 10 years before the development 
of tertiary HPT. Through literature search, we were able to find 36 reported cases of 
tertiary HPT in individuals with hypophosphatemic rickets (208, 217-226). Long 
duration and high doses of phosphate supplementations were identified as risk factors 
(217, 221). The caclimimetic cinacalcet has been reported to successfully treat 
tertiary HPT in both children (208, 227) and adults (228, 229). Recently however, the 
US Food And Drug Administration stopped all further clinical trials investigating the 
effects of cinacalcet in children after the report of the death of an adolescent study 
participant (230). The vitamin D analog paricalcitol has recently been shown to 
suppress elevated PTH in XLHR (231).  
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One male patient was treated with growth hormone from the age of 11.8 years, and 
the treatment showed a positive effect; his height z-score improved from - 3.24 before 
initiation of growth hormone (average of measurements from age 3.5-10.8 years) to 
average -2.32 from age 11.8 to age 16 years. His final height at age 16 is -2.0 SD, 
while both his parents are above average height. Three studies, one in pre-pubertal 
(232) and two in pubertal (233, 234) XLHR children, have shown a positive effect of 
growth hormone on catch up growth. Especially, growth hormone therapy in severely 
stunted children was shown to decrease the disproportion between trunk and lower 
extremity length (232). Also, growth hormone stimulated renal phosphate 
reabsorption and diminished nephrocalcinosis in XLHR (232). Other studies (235-
237) show conflicting results of growth hormone therapy, but this might be due to 
differences in anthropometric methods. Our case illustrates that, although the short 
stature cannot be completely corrected, growth hormone might prove beneficial for 
some patients, and should be considered in cases of severely reduced anticipated final 
height. 
 
5.2.2 FAM20C: novel association with hereditary FGF23 dependent 
hypophosphatemia – Paper II. 
We identified two novel mutations in the FAM20C gene in two siblings with 
hypophosphatemia and urinary phosphate wasting, but without signs of rickets, and 
demonstrated, for the first time, an association between mutations in FAM20C and 
elevated levels of intact FGF23. In retrospect, their skeletal and mineralization 
phenotype shares some features with Raine syndrome, previously described as a 
lethal condition, and recently shown to be caused by mutations in the FAM20C gene 
(238).  
 
The FAM20 gene family consists of three genes with sequence similarity, FAM20A, 
FAM20B and FAM20C, all encoding secreted glycoproteins. They were first 
identified and characterized in the search for hematopoietic growth factors (239). 
Later, Dentin Matrix Protein 4 (Dmp4), the mouse orthologoue to the human 
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FAM20C gene, was identified as a calcium binding protein, important for 
differentiation of odontoblasts in mice (240). Specifically, it was shown that 
increased expression of Dmp4 resulted in increased expression of genes important for 
mineralization in odontoblasts, ameloblasts and osteoblasts, while reduced expression 
of Dmp4 had the opposite effect.  
 
Studies on mouse embryos have shown that FAM20C is expressed during 
osteogenesis and odontogenesis, and that mutation in FAM20C causes abnormal 
calcifications in both skeletal and non-skeletal tissues. FAM20C thus seem to be 
important for proper differentiation of cells of mineralized tissues, and to inhibit 
premature mineralization of tissues during development (241). This expression 
pattern reflects to a large extent the phenotypic features of Raine syndrome, with 
distorted mineralization of bone and teeth, and ectopic calcifications in the brain. It 
was also shown that FAM20C expression in the cells and extracellular matrices of 
bone and teeth increased after birth, then declined. Taken together, this reflects a 
possible role for FAM20C in proper differentiation of the cells and prevention of 
premature mineralization of these tissues during development.  
 
In 2007 Simpson et al. identified biallelic mutations in FAM20C as the cause of 
Raine syndrome (238). This condition, first described by Raine et al. in 1989, is 
characterized by osteosclerosis of long bones and skull, leading to dysmorphic 
features, as well as intracerebral calcifications. The most severe cases are lethal 
within hours or days after birth, due to respiratory distress secondary to thoracic 
deformities.   
 
Further studies on FAM20C has shown that this is a secreted protein kinase 
previously identified as the Golgi enriched fraction casein kinase (GEF-CK) that 
specifically recognizes the consensus sequence S-x-E found in many secreted 
proteins (242-244).  Among these are the Small Integrin-Binding Ligand N-linked 
Glycoproteins (SIBLING) proteins. Specifically, it has been shown that FAM20C is 
able to phosphorylate the acidic serine aspartate rich MEPE-associated (ASARM) 
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motif of the SIBLING-proteins osteopontin (OPN), matrix extracellular 
phosphoglycoprotein (MEPE) and dentin matrix protein 1 (DMP1) (242, 243). The 
phosphorylation state of the SIBLINGs is important, as it determines the effect of the 
proteins in bone and dental development and mineralization. For instance 
phosphorylated ASARMs inhibits the differentiation of odontoblasts and osteoblasts 
and phosphorylated OPN has anti-mineralizing effects (245), while phosphorylated 
DMP1 has pro-mineralizing function (246). Non-functional FAM20C will thus have 
pro-mineralization effect by lack of OPN-phosphorylation, and anti-mineralization 
effect by lack of DMP1-phosphorylation. Functional studies have shown that survival 
beyond infancy is associated with mutations leading to partially functional FAM20C 
protein product (247), and the degree of impairment of phosphorylation correlates 
with the severity of the phenotype in previously reported cases of Raine syndrome 
(243). 
 
The two affected brothers in our study carried a p.T268M missense mutation in 
FAM20C, which has later been shown to give a partially functional protein product 
(247). The boys also carried a nonsense mutation in FAM20C, p.Y305X,  predicted to 
give truncated, nonfunctional protein. The fact that the boys had one copy of the 
FAM20C gene encoding a partially functional protein, might explain their milder 
phenotype. The parents and half brother were all clinically and biochemically 
unaffected carriers, indicating that one normal copy of the gene is sufficient to retain 
protein function. 
 
We were the first to show increased serum levels of intact FGF23 in patients with 
FAM20C mutation (178). The FAM20C protein is also directly involved in the 
regulation of FGF23, by phosphorylation of the serine in position 180 of the FGF23 
protein (247). FGF23 is normally deactivated by proteolytic cleavage at the subtilisin-
like proprotein convertase (SPC) site, 176RHTR179/S180AE182(56) (Figure 9). However, 
the O-glycosylation of T178 within this SPC site by the GalNAcT3 enzyme stabilizes 
FGF23, and prevents proteolytic degradation (56). Within the SPC site, FGF23 also 
harbors the S-x-E-motif recognized by FAM20C. The T268M missense mutation 
 64 
identified by our group has later been shown by others to lead to a partial reduction in 
the ability of FAM20C to phosphorylate FGF23 at S180 (247).  The T268M variant is 
located within the glycine-rich loop responsible for the binding of nucleotides, and 
leads to partial inhibition of O-glycosylation of FGF23 at position T178 (247). The 
lack of phosphorylation of FGF23 by FAM20C can account for the increased serum 
levels of intact FGF23 found in humans (178) and mice (248) with FAM20C 
mutations.  
 
Despite many similarities in phenotype between human and murine subjects with 
FAM20C mutations, the skeletal phenotype is not straightforward compatible in the 
two species. Fam20c KO mice show severe hypophosphatemic rickets, while 
generalized osteosclerosis is reported in humans with FAM20C mutations, including 
lethal variants of Raine syndrome. However, in a recent report, a 61 year old man 
with Raine syndrome was described to have hypophosphatemia and renal phosphate 
wasting associated with calcification of the posterior longitudinal ligament and 
increased bone mineral densities of the femoral neck, while a bone biopsy showed 
large areas of osteomalacia surrounding osteocytes (249). Such periosteocytic 
hypomineralization is typically described in bone biopsies from individuals with 
XLHR (250).  
 
Taken together, FAM20C has both pro-mineralizing and anti-mineralizing properties, 
and in humans this is reflected in the divergent effect of FAM20C mutations in 
human teeth versus human bone. In mice however, Fam20c mutations seem to cause 
a hypomineralized phenotype in both teeth and skeleton. Although there are many 
details concerning the role of FAM20C in tissue mineralization yet to be clarified, our 
work has been important for linking the observations from in vitro- and animal 
studies to human disease. FAM20C related hereditary hypophosphatemia adds to the 









Figure 9 Glycosylation and phosphorylation of FGF23 
Regulation of FGF23 break-down by the balance between O-glycosylation and 
phosphorylation of amino acids within the SPC-recognition site. a) In the normal 
state there is a balance between O-glycosylation and phosphorylation of FGF23 to 
ensure a proper balance between phosphate reabsorption and phosphate excretion. 
b) In states of defective O-glycosylation, as in FGF23- or GALNT3 mutations, 
FGF23 is predominantly phosphorylated and prone to enzymatic degradation. This 
favors phosphate reabsorption. c) In cases of FAM20C mutation, FGF23 is 
predominantly O-glycosylated at the SPC site, and thus protected from enzymatic 
degradation. This favors phosphaturia.  
c 
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5.2.3 Hereditary hyperphosphatemia illustrating the janus face of 
genes involved in phosphate regulation – Paper III 
In paper III we describe two adult siblings with hereditary hyperphosphatemia due to 
a homozygous novel mutation in the GALNT3 gene. The male had a phenotype 
predominated by hyperphosphatemic familial tumoral calcinosis (HFTC), while the 
female had a phenotype of hyperphosphatemic hyperostosis syndrome (HHS), but 
also evidence of calcific tumors characteristic for HFTC. Both had elevated levels of 
serum phosphate in combination with an increased tubular maximum reabsorption of 
phosphate relative to glomerular filtration rate (TmP/GFR). 
 
Earlier HFTC and HHS were thought to be two different conditions. However the 
observation that both are caused by mutations in the same genes (139), that both 
phenotypes can occur in one pedigree and that some subjects show a mixed 
phenotype, has led to the current view, that these phenotypes represent different 
presentation of the same condition (180, 251, 252) collectively referred to as HFTC 
(OMIM #211900).  
 
The prevalence of HFTC/HHS has, to the best of our knowledge, not been reported. 
Through our literature search, as described in paper III, we were able to identify a 
total of 56 genetically verified cases of HFTC/HHS by 2013. In addition to the two 
cases described in paper III, we were able to identify one additional case in Norway, 
described in an earlier case report (253). By repeated contact with medical and 
pediatric departments in Norwegian hospitals, we were not able to identify more than 
these three cases. The number of inhabitants in Norway by January 1st 2014 was 
5 109 000, which gives a national prevalence of this condition of 0.06 in 100.000 
inhabitants. However, as described in paper III, there are often long symptom free 
intervals, and symptoms may be nonspecific, especially in the HHS phenotype, there 
is a great possibility of under-diagnosis in this condition. In fact, the female described 
in paper III, who had mainly symptoms of HHS in adulthood, may not been 
diagnosed, had it not been for the more obvious HFTC phenotype observed in her 
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brother. Monogenic hyperphosphatemia is probably an underdiagnosed cause of 
symptomatic and non-symptomatic mineralization disorders. 
 
The siblings we describe had quite different manifestations of the same disease. The 
male had his first large calcific tumor at the elbow in adolescence, and once this was 
removed, he was apparently symptom free until the age of 37, when he had a large 
calcific tumor in the gluteal region. The diagnostic work-up suggested a clinical 
diagnosis of HFTC, although the genetic diagnosis was not made until inclusion in 
our study. The female had non-specific rheumatic symptoms throughout adulthood, 
and was diagnosed with hyperphosphatemia after screening of the males’ first-degree 
relatives. In retrospect, however, the medical files for the female described several 
attacks of diaphysitis in childhood, and also an episode of cutaneous nodules on the 
scalp in infancy. During adulthood she had dental and eye manifestations and 
calcifications of the placenta was noted in her first pregnancy. Later she had stiffness 
and pain in joints and muscles, and small calcific tumors in the subcutaneous tissue of 
hands and feet recognized on skeletal x-ray. The male also had dental manifestations 
and eye symptoms. Our findings support the observations made by others, that HFTC 
and HHS are probably to phenotypic variants for the same disease. Through our 
review of all 56 published cases of genetically verified HFTC and/or HHS, we 
showed that the combined phenotype is more common than previously recognized, 
adding further support to the theory that this is one disease with a spectrum of 
manifestations.  
 
HFTC/HHS is caused by mutations in FGF23 (143), GALNT3 (138) or KL (254), and 
the common pathophysiological mechanism is a reduced level of intact FGF23 (143). 
The levels of c-terminal FGF23 (cFGF23) are elevated, indicating increased break 
down of FGF23. This is the opposite of what is found in FGF23-dependent hereditary 
hypophosphatemia, where break down of FGF23 is prevented. The two groups of 
conditions are therefore often considered mirror images of each other, and 
biochemically this is true. However, as demonstrated in Table 7 (Appendix), 
phenotypically the image becomes more confusing. An interesting observation is that 
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the pattern of ectopic calcifications seen in the hyperphosphatemic condition 
HFTC/HHS, partially resembles the patterns of calcifications seen in FGF23 
dependent hypophosphatemic conditions. The hyperostosis of long bones 
characteristic of the HHS phenotype, is also seen in hereditary hypophosphatemia 
caused by mutations in FAM20C and DMP1 (96, 255), as well as in XLHR (196). 
Furthermore, enthesopathies are quite prevalent in adults with XLHR (196, 256).  
 
In the same way that phosphate and vitamin D supplements in HR cannot fully 
correct the skeletal mineralization defects, the various approaches to reduce serum 
phosphate seem to have variable effect in controlling ectopic calcifications in 
HFTC/HHS (257). In the collection of case reports, some authors report effect of 
phosphate lowering treatment in reducing calcific tumor size (257), but this might as 
well reflect the temporal fluctuations in disease course as seen in our patients before 
treatment and also reported by others (258). As discussed in section 3.2.2 regarding 
hereditary hypophosphatemia, the individual differences in phenotype between 
patients with the same genotype, even within the same family, probably reflects that 
physiological and pathological mineralization of tissues are complex processes. 
Hypo- and hyperphosphatemia are directly involved in pathogenesis in the two 
groups of diseases, but are also markers of FGF23 dysregulation and mineralization 
disturbance. 
 
Targeted therapy to increase the levels of FGF23 is not currently available. 
Experiments in mice have shown that overexpression of α-Klotho leads to increased 
levels of FGF23 (259). However, the negative effects of pathological levels of FGF23 
discussed earlier, suggests a narrow therapeutic range for measures to increase 
FGF23.  
 70 
5.2.4 FGF23 dysregulation – new knowledge on 
pathophysiological mechanisms in mineralization 
The last ten to twenty years, the identification of genes involved in monogenic 
phosphate balance disorders has led to new knowledge on the physiology and 
pathophysiology of phosphate regulation and mineralization process. The discovery 
of the phosphatonin FGF23 and of bone as an endocrine organ, has been important 
not only for understanding the monogenic phosphate balance disorders, but also 
disordered mineralization seen in other conditions, as chronic renal failure.  
 
Collectively, our observations suggest that adequate treatment with phosphate and 
vitamin D can only partially improve growth and heal mineralization defect in 
XLHR. It has been speculated if FGF23 may play a role in skeletal and 
mineralization metabolism independent from its role as a phosphatonin (135). 
Pathologically elevated levels of FGF23 have been associated with left ventricular 
hypertrophy (171, 172), endothelial dysfunction (173), atherosclerosis (174), and 
increased risk of mortality in chronic kidney disease (168) and persons with coronary 
heart disease (176). Treatment with phosphate triggers a vicious cycle of production 
and release of FGF23 (260) and PTH (37), which further negative effect on skeletal 
metabolism. Targeted therapy to reduce the levels of FGF23 would be a more rational 
approach, and in fact monoclonal anti-FGF23 antibodies are currently being tested in 
adult patients with XLHR. So far the results on phosphate metabolism are promising, 
and the treatment is considered safe (136, 261). The treatment has not been tested in 
children, however, and its effect on rickets and longitudinal growth in humans is not 
known, but in mice FGF23 neutralizing antibodies has been shown to correct growth 
deficiency (262). At the same time it is important to be aware of diseases associated 
with a lack of FGF23, as exemplified by the hyperphosphatemia and ectopic 
calcifications seen in hyperphosphatemic familial tumoral calcinosis (HFTC). At least 
theoretically, a balanced reduction of FGF23 levels in hereditary hypophosphatemia 
will improve mineralization defects and longitudinal growth more efficiently than by 
correcting only hypophosphatemia itself. 
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An important observation in hereditary hypo- and hyperphosphatemia is that the 
correction of serum phosphate levels towards normal, do not necessarily correct the 
disordered mineralization seen in these conditions. Also, the overlap in skeletal 
phenotypes between hypo- and hyperphosphatemic conditions illustrates the 
complexity of the bone and tissue mineralizing process. For instance, ARHR1 has 
previously been associated with rickets and short stature, as well as calcifications of 
the posterior longitudinal ligament and hyperostosis of the skull base (93). 
Furthermore, patients with FAM20C mutations, both in our cohort, and later also 
described by others have elevated levels of FGF23 (249), but no rickets or short 
stature, but rather show ectopic calcifications and hyperostosis. As discussed earlier, 
a normal serum phosphate level is probably not sufficient to ensure mineralization 
balance in the body, while the phosphorylation state of proteins can alter the balance 
between pro- and anti-mineralizing molecules. For instance osteopontin (OPN) is a 
pro-mineralizing protein in its non-phosphorylated state, while phosphorylation gives 
it anti-mineralizing properties (245). The same is seen in non-phosphorylated and 
phosphorylated ASARM peptides, which are the break down product of the SIBLING 
proteins (78, 79). In DMP1, the opposite is probably true, as phosphorylated DMP1 
has been shown to have pro-mineralizing effects (246). As discussed in section 5.2.1, 
sequence variants in FGF23 have been associated with lower levels of serum 
phosphate and lower renal tubular maximum reabsorption rate of phosphate to 
glomerular filtration rate (TmP/GFR) (206), and lower plasma intact PTH in healthy 
children and adults (207). Sequence variants in FGF23 and several other genes 
encoding proteins involved in bone metabolism, could affect sites of phosphorylation, 
and change their pro- versus anti-mineralizing properties, explaining the complex 
pathophysiology of the inherited phosphate balance disorders. 
 
Table 7 of the appendix gives an overview of the hereditary monogenic conditions 





The group of hereditary hypophosphatemias associated with rickets, and previously 
referred to as hypophosphatemic rickets, also includes conditions without clinical 
manifest skeletal disease, and we propose the term hereditary hypophosphatemia to 
depict this group of conditions. 
 
To the best of our knowledge, this is the first study of a national cohort of children 
with hereditary hypophosphatemia. Our study shows that the prevalence of XLHR of 
1 in 60.000 Norwegian children is lower than reported in earlier studies. 
 
Despite adequate treatment, all XLHR children had evidence of rickets or skeletal 
axis deviation at some point during follow up, and most had height z-scores less than 
average. A high proportion of XLHR patients had elevated PTH before the start of 
treatment with phosphate and alfacalcidol. There was a high prevalence of low-grade 
nephrocalcinosis, but only one observation of compromised renal function, which 
was transient. 
 
We have shown that patients with FAM20C mutations may have pathological serum 
levels of FGF23, and that FAM20C mutations are associated with autosomal 
recessive FGF23-dependent hereditary hypophosphatemia.  
 
We have also found a novel mutation in GALNT3 associated with HFTC and HHS, 
and brought further support to theory that these conditions are two syndromes in the 
spectrum of FGF23 related hereditary hyperphosphatemias.  
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7. Future perspectives 
The discovering of bone as an endocrine organ has brought new understanding to the 
field of phosphate metabolism generally, and hereditary phosphate balance disorders 
specifically. The differentiation between FGF23 dependent and –independent 
hereditary hypophosphatemia will be important, as FGF23 targeted therapy is 
currently in the pipeline; recombinant FGF23 neutralizing antibodies have shown to 
be safe and have beneficial effects in adults with XLHR (136, 261). If proven safe for 
use in children, FGF23 targeted therapy may also have implication for other groups 
of patients, as exemplified by chronic renal failure, in which elevated FGF23 plays an 
important role in morbidity for this large group of patients. To efficiently be able to 
select the patients eligible for FGF23 targeted therapy there is also a need for more 
robust FGF23 assays. 
 
Through exome sequencing, we were able to show that mutations in the protein 
kinase FAM20C are associated with FGF23 dependent hereditary hypophosphatemia, 
and our finding has given support to studies showing that FAM20C, through 
phosphorylation, is a regulator of FGF23. Through increasing efficiency and 
availability of genetic analysis, there may be a possibility of finding the genetic cause 
in most children with hereditary phosphate balance disorders. The highly complex 
mechanisms of phosphate homeostasis and regulation of mineralization, involve 
several genes and proteins that might be linked to monogenic phosphate balance 
disorders. 
 
Hopefully, the discovery of novel genes and novel mechanisms will contribute to a 
greater understanding of the regulation of phosphate metabolism and physiological 
and pathological mineralization processes. This includes not only disorders of 
skeletal mineralization, but also pathological vascular calcification involved in 




Through our search for families with hereditary hypophosphatemia, we identified two 
siblings with HFTC/HHS, who had symptoms from childhood, but were not 
diagnosed until late adulthood. We suggest that this condition is underdiagnosed 
because of the highly variable clinical manifestation and large fluctuation of 
symptoms over time, with long symptom free intervals. Currently available phosphate 
lowering therapy is probably not sufficient to control the ectopic calcification. 
Targeted therapy to increase the levels of FGF23 is not currently available and would 
have to be balanced against the negative effects of pathologically elevated levels of 
FGF23. However, the long-term prognosis of HFTC/HHS with currently available 
treatment is not known, and thus the indication for targeted therapy is difficult to 
determine. 
 
For children with hereditary hypophosphatemia, early recognition, genetic diagnosis 
and targeted therapy would probably give better opportunities for normal growth, and 
a therapeutic regimen that is more easy to comply with, and less risk of bothersome 
and potentially serious complications. 
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9.  Appendix 
Table 4 Age- and sex-dependent reference intervals. 
Analyte  Age  Female  Male  Unit 
S-P  At birth  0.9 – 2.2  
mmol/L 
 0 – 12 months  1.4 – 2.3  
 1 – 17 years  1.2 – 1.8  
 18 – 49 years  0.85 – 1.5  0.75 – 1.65  
 > 50 years  0.85 – 1.5  0.75 – 1.35  
S-ALP  0-14 days  90 – 273  
U/L 
 15 days < 1 year  134 – 518  
 1-5 years  156 – 369  
 5-6  149 – 363  127 – 370  
 7-8  157 – 365  149 – 345  
 9-10  166 – 423  159 – 365  
 11-13  119 – 402  150 – 492  
 14-16  49 – 291  100 – 402  
 17-19  39 – 106  55 – 242  
 Adult  35 – 105  
S-PTH  2 – 4 years  0.4  - 3.4  
pmol/L 
 4 – 8 years  0.1 – 2.7  
 8 – 12 years  0.2 – 3.4  
 12 – 16 years  0.1 – 3.9  
 Adult  1.3 – 6.9  
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Objective: Hereditary hypophosphatemias (HH) are rare monogenic conditions characterized by decreased renal tubular
phosphate reabsorption. The aim of this study was to explore the prevalence, genotypes, phenotypic spectrum, treatment
response, and complications of treatment in the Norwegian population of children with HH.
Design: Retrospective national cohort study.
Methods: Sanger sequencing and multiplex ligand-dependent probe amplification analysis of PHEX and Sanger sequencing
of FGF23, DMP1, ENPP1KL, and FAM20Cwere performed to assess genotype in patients with HH with or without rickets in all
pediatric hospital departments across Norway. Patients with hypercalcuria were screened for SLC34A3 mutations. In one
family, exome sequencing was performed. Information from the patients’ medical records was collected for the evaluation
of phenotype.
Results: Twety-eight patients with HH (18 females and ten males) from 19 different families were identified. X-linked
dominant hypophosphatemic rickets (XLHR) was confirmed in 21 children from 13 families. The total number of inhabitants
in Norway aged 18 or below by 1st January 2010 was 1 109 156, giving an XLHR prevalence of w1 in 60 000 Norwegian
children. FAM20C mutations were found in two brothers and SLC34A3 mutations in one patient. In XLHR, growth was
compromised in spite of treatment with oral phosphate and active vitamin D compounds, with males tending to be more
affected than females. Nephrocalcinosis tended to be slightly more common in patients starting treatment before 1 year of
age, and was associated with higher average treatment doses of phosphate. However, none of these differences reached
statistical significance.
Conclusions: We present the first national cohort of HH in children. The prevalence of XLHR seems to be lower in Norwegian





Hereditary hypophosphatemia (HH) is a group of rare
diseases with disordered phosphate metabolism and
decreased renal tubular phosphate reabsorption (1). In
hypophosphatemic rickets (HR), the hypophosphatemia
is associated with rickets and osteomalacia, whereas
syndromes with hypophosphatemia combined with
osteosclerosis and ectopic calcifications, and not rickets
or osteomalacia, are also recognized (1).
HR can be classified as either dependent or indepen-
dent of the bone derived fibroblast growth factor 23
(FGF23) (1). FGF23 is a phosphate-regulating hormone (2),
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sodium-phosphate co-transporter types IIa and IIc (NaPi-
IIa and NaPi-IIc) encoded by SLC34A1 and SLC34A3
respectively. Elevated levels of serum phosphate increase
the expression of FGF23 thereby decreasing the reabsorp-
tion of phosphate in the renal proximal tubule, while
hypophosphatemia normally down regulates the
expression of FGF23. FGF23 also down regulates the1-a-
hydroxylase (encoded by CYP27b1), thus inhibiting the
activation of 25OH vitamin D (25OHD) to 1,25(OH)2
vitamin D (1,25(OH)2D), and up regulates 24-hydroxylase
(encoded by CYP24a1), which inactivates 1,25(OH)2D
by conversion to 24,25(OH)2 vitamin D (3). In FGF23-
dependent HR, the physiological increase in serum
1,25(OH)2D in response to hypophosphatemia is blunted,
and the result is a serum level of 1,25(OH)2D that is low,
or inappropriately normal for the degree of hypo-
phosphatemia (4).
FGF23 dependent HR is caused by mutations in genes
involved in the FGF23 bone–kidney-axis, with levels of
intact FGF23 (iFGF23) being elevated or inappropriately
normal in the setting of hypophosphatemia when
suppressed FGF23 is to be expected (1). FGF23 dependent
HR includes X-linked dominant HR (XLHR) caused by loss-
of-function mutations in the phosphate regulating endo-
peptidase homolog, X-linked (PHEX) gene (5), autosomal
dominant HR caused by gain of function mutations in the
FGF23 gene (6), and three types of autosomal recessive HR.
ARHR1 is caused by mutations in the DMP1 gene,
encoding the dentin matrix protein 1 (7, 8), ARHR2
is caused by mutations in the ENPP1 gene encoding
the ectonucleotide pyrophosphatase/phosphodiesterase 1
(9, 10), whereas we have recently shown an association
between biallelic mutations in FAM20C and FGF23-
dependent ARHR3 in a Norwegian family (11). FAM20C
encodes a protein kinase, important in many phosphoryl-
ation processes. Phosphorylation of FGF23 by FAM20C
makes FGF23 less stable by inhibiting O-glycosylation by
GalNacT3 (12), and inactivating mutations in FAM20C
thus leads to increased levels of iFGF23 (11, 13). There is
also one report of FGF23 dependent HR caused by an
activating translocation leading to up-regulation of the
expression of the KL gene, encoding the anti-aging protein
a-klotho (14). In FGF23-independent HR, as seen in
hereditary HR with hypercalcuria (HHRH) caused by
mutations in the SLC34A3 gene (15, 16), the level of
iFGF23 is appropriately down-regulated (16).
Treatment of HR includes oral phosphate replacement
several times daily, combined with calcitriol to counteract
the secondary hyperparathyroidism (HPT) elicited by
the serum phosphate peak (17) and transient decrease
in serum ionized calcium upon phosphate dosing.
Treatment is balanced to improve linear growth and
reduce skeletal deformities while simultaneously mini-
mizing the risk of complications to treatment such as
secondary and tertiary HPT, nephrocalcinosis, hyper-
tension, and renal failure (18).
We have conducted the first complete national study
of HH in children, to explore the prevalence, genotypes,




During 2009 all pediatric hospital departments in Norway
were contacted to identify children with HH. The number
of patients identified was compared to the number of
patients younger than 18 years registered in the Norwe-
gian Patient Registry (NPR) with the diagnosis code ‘E83.3
Disorders of phosphorus metabolism and phosphatases’
in the World Health Organization’s International Classi-
fication of Diseases version 10 (WHO ICD-10). Patients
were continuously recruited through the years 2009–2014.
The inclusion criteria for HH were serum phosphate
below the age dependent reference range in repeated
samples combined with tubular maximum reabsorption
rate of phosphate per glomerular filtration rate (TmP/GFR)
not due to primary HPT, HPT secondary to renal failure or
malabsorption, Fanconi syndrome or other tubulopathy,
vitamin D dependent rickets, vitamin D deficiency or
hypophosphatemia secondary to acute metabolic
derangements. A family history or genetic diagnosis was
supportive, but not required for inclusion.
Genetic analysis
Genomic DNA was purified from blood using the
QiaSymphony System (Qiagen). If the mutation status
was not already known, all exons and intron–exon
boundaries of PHEX were sequenced in the index case of
each family. If a disease causing mutation was not found,
and the inheritance pattern suggested a sporadic case or
X-linked dominant disease, multiplex ligand-dependent
probe amplification (MLPA) analysis of PHEX were
performed at the Molecular Genetics Laboratory, Royal
Devon and Exeter Foundation NHS Trust, Exeter, Devon,
UK. The PHEX MLPA analysis can identify mid-size
deletions and insertions not detected by regular Sanger





























All exons and intron–exon boundaries of FGF23,
DMP1, ENPP1, KL, and FAM20C were sequenced, in
successive order, in subjects without pathogenic PHEX
mutations.
In short, DNA targetswere first amplified by PCR (list of
primers available upon request) using the AmpliTaq Gold
DNA Polymerase System (Applied Biosystems). PCR ampli-
cons were purifiedwith 2 ml of ExoSapIT. Using the Big Dye
Terminator chemistry sequencing was performed on the
3730 DNA analyzer (Applied Biosystems) and analyzed
using the SeqScape Software (Applied Biosystems).
All mutations detected were compared to variants
previously reported in the SNP database (http://www.ncbi.
nlm.nih.gov/projects/SNP/index.html) and in the PHEX
database (http://www.pahdb.mcgill.ca/cgi-bin/phexdb/
phexdb_mutQ1.cgi?fieldZID_mut&valueZ).
Review of medical history
Information on age at diagnosis, clinical and biochemical
findings at diagnosis, treatment, and complications was
collected by review of the medical records of included
patients. Height was converted to z-scores according to
Norwegian growth charts (19). Delta z-score was calcu-
lated as the difference between z-score at last registered
consultation and z-score at diagnosis. Laboratory data
from each visit from the time of diagnosis to the time of
inclusion in the study, including serum levels of calcium,
phosphate, alkaline phosphatase, creatinine, parathyroid
hormone (PTH), 25OHD, and 1,25(OH)2D were also
recorded, as well as results from kidney ultrasound and
skeletal X-ray examinations. TmP/GFR was calculated
according to the formula provided by Barth et al. (20).
Blood tests were analyzed according to each hospital
laboratory’s current standard methods.
Genotype–phenotype associations in XLHR patients
The PHEX mutations were classified as either deleterious
or plausible according to earlier studies (21). Deleterious
mutations comprise those leading to a premature stop
codon, including nonsense mutations, splice-site
mutations, and insertions and deletions affecting reading
frame. Mutations classified as plausible were missense
mutations and deletions that did not affect reading frame.
The phenotypic features compared were age at diagnosis
and at the last registered consultation, height z-score at
diagnosis and at the last registered consultation, serum
levels of phosphate, ALP and PTH at diagnosis, skeletal
manifestations (clinical or radiological signs of rickets or
bowing) at diagnosis, and information on dental involve-
ment, nephrocalcinosis, and persistent bowing at the last
registered consultation.
Statistical analysis
The prevalences of HH and XLHR was calculated based on
the number of patients aged 0–18 years registered with
these diagnosis in 2009 and the total number of people in
Norway aged 0–18 years by 1st January 2010, obtained
from the official Statistics Norway database (22).
The data were analyzed with SPSS version 22.
Between-group comparisons were performed using non-
parametric tests; medians were compared using theMann–
Whitney U test, and frequencies were compared with the
Fisher’s exact test.
Ethics and approvals
Written informed consent was obtained from all study
participants. The study was approved by the Regional
Committee forMedical andHealth Research Ethics, Region
West, Norway (REK number 2009/1140).




By 31st December 2009 we had identified a total of 23
children aged 0–18 years with HH in Norway, and all
except one were included in this study. Two additional
patients with HH, one with confirmed XLHR, were born
before 2009, but diagnosed after 2010. By the end of 2009
the National Patient Registry reported 32 children with
the ICD-10 diagnosis ‘E83.3 Disorders of phosphate
metabolism and phosphatases’, but four of these patients
had hypophosphatasia, and five had transient hypopho-
sphatemia in the course of malignancy, premature birth,
or other underlying condition. On 1st January 2010, the
number of inhabitants aged below 18 years was 1 109 156,
and this gives a prevalence of HH of w1 in 45 000
children. XLHR was confirmed in 18 children, giving a
prevalence of w1 in 60 000. During the period from 1st
January 2010 to 31st December 2014, we included another
four patients, two of which immigrated to Norway in 2014
and two patients born to XLHR mothers after 2010.
The total of 28 patients included comprised





























(Supplementary Figure 1, see section on supplementary
data given at the end of this article). XLHR was confirmed
in 21 children. Twenty-two patients had a family history
of HR, while six were sporadic cases.
Genotypes in HH
We identified the likely pathogenic mutation in 15 of the
19 HH pedigrees (79%). PHEX mutations were found in
21 subjects from 13 different pedigrees (Supplementary
Table 1, see section on supplementary data given at the
end of this article), and three of the XLHR probands were
sporadic. Of the 13 different PHEX mutations detected,
nine had not been previously reported in the SNP or PHEX
databases (see section ‘Materials and methods’). The nine
novel mutations comprised one large duplication, two
single nucleotide deletions leading to frameshift and
premature stop codons, two triplet deletions leading to
loss of one or more codons, two missense mutations, one
nonsense mutation, and one splice site mutation. One
male patient with HHRH was found to be compound
heterozygous for a splicingmutation, c.757-1GOA, and an
intronic deletion mutation, c.925C20_926-48del, in the
SLC34A3 gene. The c.757-1GOA affects the conserved
splice donor site of intron 7, and is predicted to cause
aberrant splicing. The c.925C20_926-48del mutation has
been reported previously (15). Two patients with com-
bined heterozygous mutations in FAM20C are described
elsewhere (11). In four patients, two sporadic cases in
females and two males with affected mothers, we were not
able to identify a pathogenic mutation by standard Sanger
sequencing of PHEX, FGF23, DMP1, ENPP1 or KL, or by
PHEX MLPA.
Phenotypes in HH
The median age at diagnosis was 2.1 years (range 0.1–15.5
years), and 26 of the 28 subjects were diagnosed before the
age of 7 years (Table 1 and detailed information for each
subject is given in Supplementary Table 2, see section on
supplementary data given at the end of this article).
Median age at the last registered consultation was
12.1 years (range 1.3–18.3).
Phenotype in XLHR " The 21 XLHR children comprised
16 females and five males. Their median age was 0.9 years
(range 0.1–15.5) at diagnosis, and 10.8 years (range 1.3–
18.0) at the last registered consultation. Growth was
compromised, and Fig. 1 illustrates the height z-scores
for 19 of the 21 XLHR patients related to age at diagnosis
and at the last registered consultation. Males tended to
have a lower height z-score than females (Table 2), both at
diagnosis and at the last registered consultation, whereas
delta z-score did not differ between the sexes. In
accordance with an earlier study (23), we analyzed the
XLHR patients’ data depending on initiation of treatment
before or after 1 year of age. There was no significant
improvement in height z-score in either treatment group.
Table 1 Characteristics of the cohort of patients with hereditary hypophosphatemiaa.
All patients (nZ28) XLHR (nZ21)
Time of diagnosis
Sex (male/female) (n/n) 10/18 5/16
Family history of HH (n/N) 22/28 18/21
Age at diagnosis (years) 2.1 (0.1 to 15.5) 0.9 (0.1 to 15.5)
Height (z-score) K0.9 (K6.5 to 1.0) K1.2 (K6.5 to 1.0)
Skeletal diseaseb (n/N) 17/28 13/21
Treatment
Age at treatment start (years) 2.1 (0.2 to 15.6) 1 (0.2 to 6.7)
Elemental phosphorus (mg/kg per day) 39 (28 to 61) 39 (0 to 74)
Alfacalcidol (ng/kg per day) 33 (21 to 42) 34 (0 to 54)
Last registered consultation
Age (years) 12.1 (1.3 to 18.3) 10.8 (1.3 to 18.0)
Height (z-score) K1.4 (K6.31 to 0.8) K1.4 (K6.3 to 0.8)
Delta z-score height (z-score) K0.1 (K3.1 to 2.0) K0.1 (K3.1 to 2.0)
Dental involvement (n/N) 13/28 9/21
Nephrocalcinosis (n/N) 11/28 9/20c
Persistent bowing (n/N) 16/28 13/21
n/N, number of patients with this characteristic/total number of patients.
aContinual variables are given as median (range).
bSkeletal disease: clinical or radiological signs of rickets, or skeletal axis deviation.





























One patient was treated with growth hormone (GH)
from the age of 11 years 10 months. His height z-score
improved from K2.9 at the last consultation before
initiation of GH to a final height of K1.9 S.D. at age
17 years (data not shown).
Clinical or radiological evidence of skeletal involve-
ment was found in 13 of 20 children (four out of fivemales
and nine out of 15 females) at diagnosis. The seven
patients without skeletal manifestations at diagnosis were
all familial cases, diagnosed before the age of 8 months
(median 4 months), and comprised six females and one
male. During the years after diagnosis, all of these had
episodes of rickets identified on clinical or radiological
examination, and a male and two of the females had
persisting skeletal axis deviations at the last registered
consultation. Overall, nine females and four males had
persisting axis deviation at the last registered consultation,
and correcting osteotomy had been performed in one
female and two males. The prevalence of dental involve-
ment was higher in male than female XLHR patients,
and in children who started treatment after the age of
1 year (Table 2).
Genotype–phenotype associations in XLHR " There
were no differences between the mutation status groups
in growth, dental involvement, persistent bowing, or
development of nephrocalcinosis (results not shown).
Treatment and complications in HH
The median age at the start of treatment was 2.1 years.
Twenty-six of the 28 patients were treated with oral
phosphate and vitamin D (alfacalcidol) supplements
(Table 1). Two patients were diagnosed at the time of
inclusion, and had not started any treatment at that point.
Treatment and complications in XLHR " Details of
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Figure 1
Growth in X-linked hypophosphatemic rickets. Ages at diag-
nosis and last registered consultation, and the corresponding
height z-scores for 19 of the 21 XLHR patients. The two outliers
represent two immigrant siblings who had not received any
medical care and did not start treatment until age 6 and
15 years respectively. The broken line represents the male
treated with growth hormone. Circles represent females and
squares represent males.
Table 2 Effect of gender and early start of treatment in X-linked hypophosphatemic ricketsa.
Stratified by gender Age at treatment start
Male (nZ5) Female (nZ16) !1 year (nZ10) O1 year (nZ9)
Time of diagnosis
Age (years) 0.9 (0.5 to 15.5) 1.5 (0.1 to 6.5) 0.4 (0.1 to 0.9) 3.3 (0.7 to 15.5)
Height (z-score) K3 (K5.1 to 0.5) K0.9 (K6.5 to 1.0) K0.8 (K3.0 to 1.0) K2 (K6.5 to 0.5)
Skeletal diseaseb (n/N) 4/5 9/15 3/10 9/9
Treatment data
Age at treatment start (years) 1 (0.5 to 3.6) 1.1 (0.2 to 6.7) 0.6 (0.2 to 1.0) 3.6 (1.2 to 15.6)
Elemental phosphorus (mg/kg per day) 50 (32 to 64) 32 (0 to 74) 59 (11 to 74) 35 (28 to 67)
Alfacalcidol (ng/kg per day) 49 (37 to 54) 28 (0 to 48) 42 (17 to 54) 26 (17 to 37)
Last registered consultation
Age (years) 14.8 (6.5 to 16.3) 7.9 (1.3 to 18.0) 11.1 (1.3 to 18.0) 8.4 (3.2 to 16.3)
Height (z-score) K2.2 (K5.1 to K1.0) K1.4 (K6.3 to 0.8) K1.4 (K2.6 to 0.8) K2 (K6.3 to 0.3)
Delta z-score (z-score) 0 (K2.1 to 1.3) K0.2 (K3.1 to 2.0) K0.4 (K3.1 to 2.0) 0 (K1.1 to 1.3)
Dental involvement (n/N) 4/5 5/15 2/10 7/9
Nephrocalcinosis (n/N) 2/5 7/15 7/10 2/9
Persistent bowing (n/N) 4/5 9/15 5/10 7/9
n/N, number of patients with this symptom/total number of patients.
aContinual variables are given as median (range).





























patients. In this group, the median age at the start of
treatment with oral phosphate and alfacalcidol was 1.0
year (range 0.2–15.6), and ten of 19 children started
treatment before the age of 1 year.
Information concerning development of nephrocalci-
nosis was available for 20 of 21 XLHR patients, and
nephrocalcinosis was diagnosed in nine of 20 (45%),
at a median age 4 years 6 months (range 1 year–5 years
5 months), after a median time in treatment of 1 year
5 months (range 8 months–4 years 5 months). The
median time in treatment for patients without registered
nephrocalcinosis was 7 years 2 months (range 0–14 years
7 months).
All nine XLHR patients who developed nephrocalci-
nosis did so within 5 years of treatment. Of the 11 patients
without nephrocalcinosis, only four had been treated for
5 years or more, and were included in further compari-
sons. The prevalence of nephrocalcinosis in this subgroup
was nine of 13 (69%). There was a trend toward a higher
average daily dose of phosphate (given as mg/kg per day
elemental phosphorus) during the years before the
diagnosis of nephrocalcinosis as compared to the daily
phosphate dose during the first 5 treatment years in
patients without nephrocalcinosis (Fig. 2A) (median
61.0 mg/kg per day (range 12.1–79.0) and median
44.8 mg/kg per day (range 13.8–64.7) respectively). More-
over, there was a tendency for earlier start of treatment in
children who developed nephrocalcinosis compared
with children that did not (median 0.5 year vs 1 year;
range 0.2–4.4 vs 0.6–3.6), and seven of nine children with
nephrocalcinosis and two of four children without
nephrocalcinosis had started treatment before 1 year of
age. There were no differences in the starting doses of
phosphate and alfacalcidol, average daily dose of alfacal-
cidol, serum level of PTH level at diagnosis, maximum
registered serum PTH, or maximum registered urine-
calcium/creatinine ratio (U-Ca/creatinine; results not
shown). Furthermore, the groups did not differ with
respect to the occurrence of skeletal symptoms at
diagnosis, dental involvement at diagnosis, persistent
bowing at the last registered consultation, or delta height
z-score (not shown).
Information concerning parathyroid state was avail-
able in 18 patients, of whom 16 had elevated levels of total
intact PTH at the time of diagnosis (Table 1 and
Supplementary Table 2a). All patients developed transient
HPT during treatment in the face of normocalcemia. As
seen in Fig. 2B, there was a positive association between
the maximum measured serum PTH and the daily dose
of phosphate (given as mg/kg per day of elemental
phosphorus). Tertiary HPT was diagnosed in one female
XLHR patient at 13 years of age. She had been treated with
phosphate and alfacalcidol from the age of 5 months, and
during the 12.5 years of treatment, the average phosphate
dose was 83.0 mg/kg per day (range 47.0–127.0 mg/kg
per day) and alfacalcidol dose 18.5 ng/kg per day (range
11.4–44.0 ng/kg per day). Treatment with calcimimetics
was started, and she has avoided the need of para-
thyroidectomy (24).
Treatment and complications in non-X-linked
HH " Nephrocalcinosis was diagnosed in one female
patient with no detected mutation in any of the known
genes at age 8 years 2 months after 6 years 4 months of
treatment with phosphate and alfacalcidol. Nephrocalci-
nosis was also demonstrated in the male patient with
HHRH, before start of treatment. Tertiary HPT was found
in one female patient with no established mutations in
any of the known genes. She had been treated for 14 years,
with an average dose of elemental phosphorus of
45.9 mg/kg per day (range 38–80 mg/kg per day) and
alfacalcidol 34.2 ng/kg per day (range 22–49.6 ng/kg per
day) the last 7 years before the development of perma-
nently elevated PTH combined with hypercalcemia. The
patient has responded well to treatment with a calcimi-
metic, and has so far not needed parathyroidectomy.
Discussion
We have presented the first national cohort of HH and
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Figure 2
Complications in X-linked hypophosphatemic rickets.
(A) Nephrocalcinosis: the average daily phosphate (given as
mg/kg per day elemental phosphorus) dose in patients who
developed nephrocalcinosis (NCC) and patients who did not
(NCK). The horizontal lines represent themedian in each group.
(B) Hyperparathyroidism: the relationship between the maxi-
mum registered value of serum PTH and phosphate dose (given





























phenotypic spectrum, and response to and complications
of treatment in the Norwegian pediatric population. The
prevalence of XLHR in Norwegian children was one in
60 000. Earlier reports from regional cohorts, with a risk of
selection bias, have found the prevalence of XLHR to be
w1 in 20 000 (25, 26). Studies of large pedigrees of XLHR
patients have reported a low penetrance of skeletal
manifestations in hypophosphatemic female family
members, whereas all hypophosphatemic males had
skeletal manifestations of disease (27). Hence, there is a
possibility of undiagnosed XLHR in Norwegian females
from pedigrees without affected males. However, the ratio
of female to male patients in our cohort was 16:5, as
compared to the expected ratio of 2:1 for X-linked
dominant disorders; a large proportion of undiagnosed
females thus seems unlikely. Since our study included only
children already in contact with health care and asympto-
matic members of the pedigrees were not tested for
hypophosphatemia, we cannot rule out hypophosphate-
mic second-degree relatives (28). It is therefore possible
that the prevalence of HH and XLHR in the Norwegian
pediatric population may be higher than one in 45 000
and one in 60 000 respectively.
We identified the genotype responsible for HH in 79%
of pedigrees in this population-based cohort, and PHEX
mutations comprised 87% of the verified mutations. This
supports what has been found by others (29), and confirms
that XLHR is the most common variant of HR. Of 13 PHEX
mutations, nine (69%) had not been reported earlier
(ExAC Browser accessed 21.05.15, http://exac.broadinsti-
tute.org/gene/ENSG00000102174), demonstrating that
most mutations are private in this gene (28). We have
previously reported two male siblings with the first
identified association between compound heterozygous
mutations in FAM20C and FGF23 dependent hypo-
phosphatemia in humans (11). None of the patients had
mutations in FGF23,DMP1, ENPP1, or KL, confirming that
mutations in these genes rarely seem to be the cause of
HH. In four patients we did not find the likely disease
causing mutation. However, as illustrated by our finding
of FAM20C mutations (11), there are possibilities of
mutations in other genes associated with pathways
involving FGF23, phosphate reabsorption, and tissue
mineralization.
One adolescent male was compound heterozygous for
mutations in the SLC34A3 gene. He had nomanifestations
of rickets, normal growth and bone mineral density, and
came to medical attention because of recurrent kidney
stones, accompanied by hypercalcuria, hypophosphate-
mia, suppressed PTH, and high 1,25(OH)2D. He had a
novel splicing mutation c.757-1GOA affecting the con-
served splice donor site of intron 7, predicted to cause
aberrant splicing, and a previously reported intronic
deletion mutation, c.925C20_926-48del (15). Earlier
studies have shown that about 10% of homozygous and
16% of compound heterozygous carriers of mutations in
SLC34A3 presented with renal calcifications, without
evidence of skeletal involvement (30, 31). Thus, our case
is consistent with a phenotypic and genotypic hetero-
genesity in SLC34A3 related conditions, including HHRH.
When comparing non-sense PHEX mutations with
missense PHEX mutations likely to reduce protein
function, we did not find differences in growth, severity
of skeletal or dental disease, or in the prevalence of
treatment complications based on the type of mutation.
Our findings confirm the results of another recent study
(21), whereas other studies have suggested an association
between truncating mutations and a more severe skeletal
phenotype (32, 33, 34). However, even in subjects with the
same genotype, the skeletal phenotype seems to be very
variable and individual (35, 36). This might reflect
influence from other genetic variants in mineralization
and phosphate metabolism. Interestingly, it was recently
reported that patients homozygous or heterozygous
for the FGF23 sequence variant c.C716T (p.T239M,
rs7955866) had significantly lower levels of serum
phosphate and lower renal TmP/GFR than patients
homozygous for the WT allele (37). Another research
group have reported a weak, but significant association
between the c.C716T variant of FGF23 and lower
TmP/GFR and lower plasma intact PTH in healthy children
and adults (38). In none of the studies, it was possible to
show significantly higher levels of serum iFGF23 in
subjects carrying the c.C716T variant.
Evaluation of phenotype in XLHR showed that growth
was compromised, and there was a tendency for lower
height z-scores in males than females. Also, we found a
trend for males having a higher proportion of skeletal and
dental manifestations than females. As discussed above,
some studies points to a milder phenotype in females,
with slight hypophosphatemia and mild or no overt
skeletal disease (39, 40). There are also reports of slightly
lower serum levels of phosphate (40, 41) and more severe
skeletal disease in male than female XLHR patients (42).
Other studies have reported no gender differences in
skeletal phenotype (35, 43), but more severe dental
phenotype in post pubertal males than females (35, 44).
Thus, our findings support the notion of a more severe





























Dental involvement seemed to be less common in the
patients who started treatment before 1 year of age,
suggesting the importance of proper mineralization of
dentin prior to the eruption of teeth (45). On the other
hand, starting treatment before age 1 year did not lead to
an improved height z-score at the last registered consul-
tation. Some earlier studies have concluded that early start
of treatment had a positive effect on linear growth (23, 46).
In one study however, the height z-score was generally
higher in those who started treatment before the age of
1 year compared with those who started later, but declined
over time for those who started treatment early and
improved in those who started treatment later (46). We
found that treatment with phosphate and vitamin D
improved mineral homeostasis and rickets, but did not
fully correct skeletal axis deviation and to a lesser extent
correct the growth deficiency in HR. This adds support to
the theory that FGF23 may play a role in the normal
physiology of mineralized tissues independently phos-
phate regulation (18). Treatment with phosphate will lead
to transient increases in serum phosphate, which trigger
production and release of FGF23 (47) and PTH (48), further
aggravating the skeletal phenotype. Novel therapy with
FGF23 neutralizing antibodies has shown that inhibition
of excess FGF23 activity correct growth deficiency in mice
(49), and anti-FGF23 antibodies are currently being tested
in human XLHR (50, 51). It is possible that longitudinal
growth in HH patients reflects the individual severity of
and response to a disturbed FGF23 homeostasis, rather
than the severity of hypophosphatemia itself.
The patients who developed nephrocalcinosis had
started treatment earlier and had received higher daily
doses of phosphate, but did not have better growth
outcomes, than patients without nephrocalcinosis. Renal
function remained normal in all patients, except for
transient low-grade renal failure seen in the XLHR patient
with tertiary HPT. Our results strengthen the association
between higher phosphate doses and development of
nephrocalcinosis found in earlier studies (52, 53, 54, 55).
Early start of treatment as a risk factor for nephrocalcinosis
has been found by some (52), but not by others (23, 46, 56).
The prevalence of nephrocalcinosis in patients receiving
combination therapy with phosphate and calcitriol is
reported to be from 33 to 80% (median 59%) (23, 46, 52,
53, 54, 55, 56, 57, 58), but long term follow-up of mild
nephrocalcinosis in XLHR does not seem to affect renal
function (56). As discussed above, treatment with
phosphate and calcitriol has a certain positive effect on
growth, but only phosphate-treated patients develop
nephrocalcinosis (54, 55, 56). This again probably
reflects that current treatment options are suboptimal,
both when considering skeletal outcome and the rate of
complications.
Elevated serum levels of PTH were found in ten of 15
XLHR patients before the start of treatment all patients
developed HPT during the course of treatment. Our
findings add to other reports of high normal or slightly
elevated levels of PTH in hypophosphatemic untreated
XLHR patients (59, 60, 61). In normal subjects, hypopho-
sphatemia will, through an increase in 1,25(OH)2D, reduce
PTH levels (62). Evidence also suggests an inhibitory
effect of FGF23 on PTH production (63). The explanation
for the inappropriate PTH response in untreated HR, and
the details of the interactions between phosphate, FGF23,
and PTH, still need further clarification.
Secondary HPT caused by oral phosphate supplements
can be counteracted by increasing the doses of calcitriol,
with the risk of developing hypercalcuria and nephrocal-
cinosis, or by reducing the phosphate dose, with the risk
of worsening rickets (64). However difficult, successful
management of HPT in XLHR is important, as HPT has
been associated with development of hypertension and
renal failure (24, 65), cardiac failure (66), and also brown
tumor in the mandible (67).
Two patients, one with XLHR, developed tertiary HPT
after long-term use of phosphate supplements. The XLHR
patient had received relatively high doses of phosphate
and relatively low doses of alfacalcidol for more than
10 years. Tertiary HPT has been reported in 36 cases of HR
(24, 65, 66, 68, 69, 70, 71, 72, 73, 74, 75), and prolonged
treatment with high doses of phosphate supplements
seems to be a risk factor (68, 71). There are reports of
successful treatment of tertiary HPT with cinacalcet in
children (24, 76) and adults (77, 78), but safety concerns
have stopped further clinical trials investigating the effects
of cinacalcet in children (79). A recent report suggests the
vitamin D analog paricalcitol to suppress elevated PTH
secondary to treatment in XLHR (80). However, careful
monitoring of treatment, to ensure lowest efficient
phosphate dose is very important to heal rickets and at
the same time reduce the risk of tertiary HPT.
The observations from this study support recently
published guidelines on treatment and monitoring of HR
in children (64, 81). We recommend that combined
treatment with oral phosphate and activated vitamin D
(calcitriol or alfacalcidol) is started once the diagnosis has
been made. Most children respond well to a calcitriol dose
of 20–30 ng/kg per day (divided in two doses) or
alfacalcidol 30–50 ng/kg per day (single dose) and an





























(divided in four doses) with reduced signs of rickets and
skeletal deformities. The starting doses of phosphate
should be kept low to reduce gastrointestinal side effects,
and to avoid complications clinical and biochemical
controls should be performed at least every 3 months,
and supplemented with skeletal X-rays every 2 years and
renal ultrasonography every 2–5 years. To avoid HPT, the
aim should not be normalization of serum phosphate, but
the lowest efficient dose that promote growth and heal
rickets. To minimize the risk of nephrocalcinosis, hyper-
calcuria, defined as U-Ca/creatinine ratio O0.87 mmol/
mmol should be avoided.
One strength of our study is related to the fact that
combined data from the NPR and all pediatric centers in
Norway allowed us to collect a complete national material
of childhood HH. This allowed for the estimation of a
national prevalence, and adds information to the litera-
ture on the epidemiology of hereditary HR. Moreover, we
have identified newmutations in known and novel genes,
expanding the genetic diversity of HH with and without
rickets. On the other hand, the study is limited by the size
of the cohort and the retrospective design, implying we
could not ensure uniform collection of information from
the clinical, biochemical, and radiological examinations.
Furthermore, we did not do genetic testing on normopho-
sphatemic, asymptomatic siblings, as predictive genetic
testing on children is not allowed in Norway according to
the Biotechnology Act. This means there is a possibility for
undiagnosed subclinical cases.
In conclusion, we have presented the first complete
national cohort of HH in children. The prevalence of
XLHR seems to be lower in Norwegian children than
reported earlier.
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Long-term clinical outcome and phenotypic
variability in hyperphosphatemic familial tumoral
calcinosis and hyperphosphatemic hyperostosis
syndrome caused by a novel GALNT3 mutation;
case report and review of the literature
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Abstract
Background: Hyperphosphatemic Familial Tumoral Calcinosis (HFTC) and Hyperphosphatemic Hyperostosis Syndrome
(HHS) are associated with autosomal recessive mutations in three different genes, FGF23, GALNT3 and KL, leading to
reduced levels of fibroblast growth factor 23 (FGF23) and subsequent clinical effects.
Results: We describe a consanguineous family with two affected siblings with HFTC and HHS caused by a novel
homozygous G-to T substitution in exon 3 of GALNT3 (c.767 G > T; p.Gly256Val), demonstrating great phenotypic
variation and long asymptomatic intervals. Calcific tumors appeared at 14 years of age in the male, and the female
displayed episodic diaphysitis from age 9 years. Symptoms of eye involvement were present in both from childhood,
and progressed into band keratopathy in the female. Abnormal dental roots and tooth loss, as well as myalgia were
present in both from their mid-twenties, while the female also had calcifications in the placenta, the iliac vessels and
thyroid cartilage. New calcific tumors appeared more than 20 years after the initial episodes, delaying diagnosis and
treatment until the ages of 37 and 50 years, respectively. Both siblings had elevated serum phosphate levels, inappropriately
elevated tubular maximum phosphate reabsorption per unit glomerular filtration rate (TmP/GFR), reduced levels of intact
FGF23 and increased levels of c-terminal FGF23. Review of all 54 previously published cases of GALNT3, FGF23,
and KL associated HFTC and HHS demonstrated that more subjects than previously recognized have a combined
phenotype.
Conclusion: We have described HFTC and HHS in a consanguineous Caucasian family with a novel GALNT3 mutation,
demonstrating new phenotypic features and significant variability in the natural course of the disease. A review of the
literature, show that more subjects than previously recognized have a combined phenotype of HFTC and HHS. HHS
and HFTC are two distinct phenotypes in a spectrum of GALNT3 mutation related calcification disorders, where the
additional factors determining the phenotypic expression, are yet to be clarified.
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Background
The last decade has brought new insight into the molecular
and pathophysiological aspects of phosphate metabolism.
Previously, the regulation of serum and body phosphate
was thought to be merely a consequence of the regulation
of calcium levels by parathyroid hormone (PTH) and vita-
min D. It is now accepted that the regulation of phosphate
is specific, and involves phosphatonins, in particular fibro-
blast growth factor 23 (FGF23) [1].
Hyperphosphatemic familial tumoral calcinosis (HFTC) is
a rare monogenic disorder with disturbances in the hormo-
nal regulation of phosphate levels by FGF23, leading to soft
tissue calcifications [2]. Hyperphosphatemic hyperostosis
syndrome (HHS) is characterized by hyperphosphatemia
and episodes of diaphysitis and cortical hyperostosis visual-
ized on x-rays. This was thought to be a separate entity,
rarely occurring together with HFTC, but it has later been
shown that the same genes and same mutations are involved
in both HHS and HFTC. This has led to the current opin-
ion, that HHS and HFTC are different manifestations of the
same genetic defect, and that in some families the same mu-
tation can lead to either phenotype [3-5]. Both conditions
are caused by inactivating mutations in either the FGF23
gene encoding the phosphaturic hormone FGF23 [6,7], or
the GALNT3 gene encoding the UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-acetylgalactosaminyltransferase
3 (GalNAc-T3) enzyme [8]. This enzyme is necessary
to glycosylate FGF23, thereby preventing the break
down and inactivation of the functional full-length ver-
sion of the protein [9]. There is also one report of
HFTC caused by an inactivating mutation in the KL
gene, encoding α-Klotho, which is an essential co re-
ceptor for the FGF23 receptor function in phosphate
regulation [10].
GALNT3-associated HHS and HFTC are rarely found
in Caucasians [11]. In this report we describe a consan-
guineous family of Norwegian origin, with a novel
homozygous mutation in exon 3 of GALNT3, where
diagnosis and treatment were delayed until late adult-
hood. In addition to new phenotypic features, the cases
demonstrate the significant variability in the natural
course of the disease, and how features of HFTC and
HHS can be substantially overlapping with time, even
in the same patient.
Methods
Patients
The family was recruited from a national population-based
cohort of familial hyperphosphatemia in Norway. Written
informed consent was obtained from all study participants.
The study was approved by the Regional Committee for
Medical and Health Research Ethics, Region West, Norway
(REK number 2009/1140).
Biochemical parameters
Blood samples were collected after an overnight fast.
Circulating levels of calcium, albumin, phosphate and al-
kaline phosphatase (ALP) activity in serum were analyzed
using the Modular P-system from Roche Diagnostics
(Basel, Switzerland). PTH was measured with a two-site
chemiluminescent enzyme-labeled immunometric assay for
intact PTH (Immulite 2000, Siemens Healthcare Diagnos-
tics, Deerfield, IL, USA). Measurement of 25(OH)D levels
was performed using an in-house developed liquid chroma-
tography double mass spectrometry (LC-MS/MS) method
[12]. A spot sample of urine collected at the time of blood
sampling was analyzed for calcium, phosphorus and cre-
atinine. The maximal tubular reabsorption of phosphate
per glomerular filtration rate (TmP/GFR) was calculated
according to the algorithm based on the nomogram of
Walton and Bijvoet [13,14]. Plasma intact FGF23 (iFGF23)
was measured with the FGF23-ELISA kit (Kainos Labora-
tories, Japan), with a lower detection limit of 3 pg/ml and a
coefficient of variation (CV) of 4%. Plasma C-terminal
FGF23 (cFGF23) was measured using the FGF23 sec-
ond generation C-terminal ELISA kit (Immutopics, San
Clemente, CA, USA), with a lower detection limit of 1.5
RU/ml and a CV of 4.7%.
Bone mineral density
The bone mineral density (BMD) of the right hip and
lumbar spine was measured with dual X-ray absorpti-
ometry (DXA) using Hologic Delphi W (Hologic inc.,
Bedford, Massachusetts, USA).
Genetic analysis
Genomic DNA was purified from blood using the Qia-
Symphony system (Qiagen, Hilden, Germany).
All exons and intron-exon boundaries, of GALNT3, KL
and FGF23 were sequenced in subject 1 (the index case).
Only exon 3 of GALNT3 was sequenced in subject 2 as well
as in the 7 asymptomatic family members (Subjects I-2,
II-2, II-4, III-1, III-3, IV-1, IV-2 in Figure 1) and 192
healthy blood donors.
DNA targets were first amplified by polymerase chain re-
action (PCR) (list of primers available upon request) using
the AmpliTaq Gold® DNA polymerase system (Applied bio-
systems, Life biosystems, Carlsbad, California, USA. PCR
amplicons were purified with 2 μl of ExoSapIT®. Using the
Big Dye Terminator® chemistry sequencing was performed
on the 3730 DNA analyzer, (Applied biosystems) and ana-
lyzed using the SeqScape® software (Applied biosystems).
Strategy of the literature review
We searched PubMed and EmBase for case reports on
HFTC and HHS caused by mutations in GALNT3, FGF23
and KL using the search terms “hyperphosphatemic tumoral
calcinosis”, “hyperphosphatemia hyperostosis syndrome”,
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“GALNT3 mutation” and “FGF23 mutation” and “KL muta-
tion”. Some cases and pedigrees were described in several
papers, including earlier papers on the clinical presentation
and later papers describing disease progression and genetic
diagnose. In these cases we included all papers. We did not
include case reports describing pedigrees or cases where a
genetic diagnosis was not made.
Results
Case reports
Subject 1 is a Caucasian male, the youngest of five siblings
of a consanguineous marriage (Table 1); the parents have
a common ancestor eight generations back. He presented
with a calcified mass on his right elbow at age 14. This
mass was removed, the histological diagnosis was tumoral
calcinosis, but no treatment or follow up was initiated.
Prior to this episode he had chronic conjunctival irritation
and abnormal dental roots shown on x-ray. Dental ab-
scesses and spontaneous tooth loss started at 25 years of
age. There were no new calcific tumors until the age of 35,
when he developed a tender mass in his left gluteal area.
He was eventually diagnosed with HFTC at age 37, when
he presented with a 6 × 8 cm calcification over his left
ischial tuberosity (Figure 2a), hyperphosphatemia, an in-
appropriately high TmP/GFR of 1.46 and TRP 84%. His
renal function and serum calcium were normal. Serum
1,25 dihydroxyvitamin D3 was inappropriately normal in
the setting of hyperphosphatemia and serum intact PTH
was low (Table 2). Therapy with the phosphate binder
Sevelamer 1600 mg three times daily was started, but the
patient discontinued medication after one year due to non-
medical circumstances. At age 41 his left gluteal mass had
increased further, to the degree that it restricted his daily
activity. Spontaneous rupture of the overlying skin resulted
in discharge of a white matter and transient pain relief, but
there was rapid relapse. Sevelamer 4.8-6.4 g per day was
tried once again, but had no effect on tumor size or serum
phosphate levels.
At 42 years old his left gluteal mass had not decreased
despite treatment for one year. He had general myalgia,
with pain and stiffness in calves and forearms after slight
activity. Clinical examination revealed a large, tender
mass in the left gluteal area, displacing the natal cleft to
the right, and the calves felt hard on palpation. Eye exam-
ination revealed salt-like conjunctival deposits. All his per-
manent teeth had been substituted by implants, but dental
health was otherwise good. His height was 172.2 cm, head
circumference was 59 cm and blood pressure was 110/
80 mmHg. Computerized tomography of the kidneys and
abdomen was normal. Bone mineral density (BMD) of the
femoral neck and total hip was relatively high (T-scores
1.3 and 1.9; Z-scores 1.9 and 2.2, respectively), while lum-
bar spine BMD was normal (T-score 0.4; Z-score 0.5). In
conclusion, he has had manifestations of classic HFTC
from childhood. The long interval between development
of calcific tumors has delayed diagnosis and treatment.
Subject 2 is the older sister of subject 1. She was diag-
nosed with HFTC at the age of 50 upon serum phosphate
screening of the first-degree relatives of subject 1. A re-
view of her past medical record revealed an episode of
several cutaneous tumors on her scalp at three weeks of
age. At age six years she had a large tumor in the gluteal
Figure 1 Pedigree.
Table 1 FGF23 levels
Individual1 Ref. range Unit I-2 II-2 II-3 II-4 II-5 III-1 III-3
Genotype2 M/m M/m m/m M/M m/m M/M M/m
i-FGF23 21.6-70.23 pg/ml 66.3 51 26.8 33.0 12 47.2 53
c-FGF23 10-802 RU/ml 32.2 25.2 120 34.8 210 17.2 20.2
1Individuals, as presented in Figure 1.
2M = wild-type allele; m = mutant allele.
3Reference range valid for the laboratory used for this study.
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area, and at age seven years a large tumor on her right
thigh; both tumors were incised, but no diagnose is
noted in her medical records. Between the ages of nine
and 12 years, she had three episodes of unilateral leg
pain lasting for several weeks and treated with antibi-
otics for suspected osteomyelitis; blood cultures were
sterile and x-rays showed sclerosis of the tibia and peri-
osteal thickening with onionskin configuration. At age
25 she had a new episode of leg pain, but this time the
radiological examinations were negative, and she received
no treatment. From her twenties, she has had conjunctival
irritation and dental problems similar to her brother. At
age 22 she gave birth to a healthy boy one week before
term date after an uneventful pregnancy; the placenta was
highly calcified, but the baby had no signs of intrauterine
growth restriction (birth weight 3400 g, length 51 cm,
head circumference 36 cm). Her second pregnancy was
uncomplicated, but birth records are not available. She has
had no stillbirths or spontaneous abortions.
In adulthood her chief complaint has been myalgia,
stiffness of knees, hips and shoulders, and pain and de-
formities of her fingers and feet. The clinical findings re-
sembled osteoarthritis, but the rheumatologic diagnostic
work up was inconclusive. X-rays showed pronounced
calcifications and degenerative changes in and around
the phalanges of her hands and feet, calcifications of soft
tissues in the foot, large bilateral calcaneal enthesopathies
and age-inappropriate calcification of the thyroid cartilage
(Figure 2b). Blood tests at age 50 (Table 2) revealed hyper-
phosphatemia, normal kidney function and inappropriately
elevated renal tubular reabsorption of phosphate. The serum
level of calcium was slightly elevated, but the serum levels of
PTH and 1.25 (OH)2 vitamin D3 were not available.
At 55 years of age she had been treated with Sevelamer
800 mg per day for the previous three years, and both her
symptoms and serum phosphate level had remained stable.
Clinical examination revealed a height of 163.3 cm, head
circumference was 56 cm and blood pressure was 120/
70 mmHg. She had salt-like deposits on her bulbal con-
junctiva, and the ophthalmology report confirmed band
keratopathy but normal vision. She had some dental im-
plants but good dental health. Findings in her hands, knees
and hips were as previously noted. In addition her calves
felt stiff on palpation. Computerized urography showed
normal kidneys, but calcifications in the iliac vessels. BMDs
of the femoral neck, total hip and lumbar spine were all
normal (T-scores 1.5, 0.5 and 0.4; Z-scores 2.6, 1.2 and 1.5,
respectively). We conclude in retrospect that she first man-
ifested symptoms HHS in childhood, and that the absence
of calcific tumors has led to delayed diagnosis.
Biochemical profile at the time of diagnosis and inclu-
sion is given in Table 2.
FGF23
The plasma intact and c-terminal FGF23 were measured
at enrolment. The level of intact FGF23 was decreased
and c-terminal FGF23 was elevated in the two affected
Figure 2 Radiographic findings. The pictures show a) the left gluteal calcification in subject 1, and b) age-inappropriate thyroid cartilage
calcifications in subject 2.




Unit Subject 1 Subject 2
T1 T2 T1 T2
s-Phosphate M: 0.85-1.65 mmol/L 1.81 2.21
F: 0.85-1.50 1.6 – 1.84 1.36
s-Calcium 2.15-2.51 mmol/L 2.37 2.36 2.5 2.64
s-iPTH 1.6-6.9 pmol/L 0.8 1.4 NA 5.2
s-Creatinine M: 60-105 μmol/L 72 78
F: 45-90 73 61
i-FGF23 26.1-70.21 pg/ml NA 12 NA 26.8
c-FGF23 10-801 RU/ml NA 210 NA 120
1,25(OH)2 vit D 50-150 nmol/L 85 87 NA 54
TmP/GFR > 0.85 mmol/L 1.46 2.07 1.41 1.12
TRP > 80 % 84 94 88 82.5
1Reference range valid for the laboratory used for this study.
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subjects (Table 1); the deviation from normal was more
pronounced in the male than in the female. The unaffected
healthy family members had normal levels of iFGF23 and
cFGF23 (Table 1).
Genetic analysis
Subject 1 was screened for mutations in all exons of FGF23,
GALNT3 and KL. No mutations were found in FGF23 or
KL, but a novel homozygous G-to T substitution in exon 3
of GALNT3 (c.767 G>T) was identified, resulting in an
amino acid change in position 256 (p.Gly256Val) (Figure 3).
Subject 2 was also homozygous for this mutation, while
her son and mother were heterozygous carriers. Subjects
II-2, II-4, III-1, IV-1 and IV-2 did not carry the mutation.
This substitution was not found in 192 healthy blood
donors.
The detected mutation is not described in available data-
bases and both the nucleotide and amino acid positions are
highly conserved (phyloP: 5.86 and conserved up to C. ele-
gans), and the variant is predicted as pathogenic by several
prediction programs such as Polyphen2 [15], Align GVGD,
MutationTaster and SIFT.
Review of the literature
A summary of all articles describing HFTC and HHS in
subjects with GALNT3, FGF23 and KL mutation is given
in Additional file 1: Table S1.
In addition to the two subjects in this report, our search
of the literature identified a total of 40 articles describing
54 affected subjects. This gives a total of 56 subjects (30
male; 26 female) from 35 different pedigrees. In 12 of the
previously described cases of HFTC and one of the cases
of HHS, we found that the cases had actually a com-
bined phenotype of HFTC + HHS (“Phenotype revised”
in Additional file 1: Table S1).
Genotype and phenotype
GALNT3 mutations were identified in 42 cases (22 men,
20 female; 75%) (Figure 3), FGF23 mutations in 13 cases
(8 male, 5 female; 23%), and a KL mutation was found in
one female subject (2%). HFTC was the dominating
phenotype in subjects with GALNT3 mutations, whereas
in subjects with FGF23 mutation, HFTC and the com-
bined HFTC +HHS phenotype were equally represented
(Table 3). Interestingly, the isolated HHS phenotype was
not found in subjects with FGF23 mutation. Dental in-
volvement was reported more often in subjects GALNT3
than FGF23 mutation (43% and 23%, respectively), whereas
vascular calcification seemed more common with FGF23
mutation than with GALNT3 mutation (23% and 14%,
respectively). Eye involvement was reported equally with
both genotypes.
Sex and phenotype
Overall, males tend to have the phenotype of classic
HFTC (60% of men), while females more often have mani-
festations of hyperostosis (HHS alone or HFTC+HHS; 56%
of women) (Table 3). Vascular calcification was assessed in
18 cases, and was reported to occur more often in females
than in males, whereas dental and eye involvement were re-
ported more often in males (43% and 20% of the males and
32% and 12% of the females, respectively).
Discussion
We describe a consanguineous Caucasian family with two
affected siblings carrying a novel homozygous missense
mutation in exon 3 of the GALNT3 gene. The male has
classic HFTC and the female had one episode of cutane-
ous nodules on her scalp in infancy and episodes of HHS
in childhood.
Figure 3 GALNT3 variations [3,4,8,11,18,22,26-36]. The figure shows the position of the amino acid changes associated with HFTC and/or
HHS. The amino acid changes are placed in boxes corresponding to the observed phenotype; green box means HHS, blue box means HFTC and
red box means the combined phenotype HFTC + HHS. Mutations placed above the figure are predicted to damage protein function, while
missense mutations are placed below the figure. The orange box represents the transmembrane domain (TM, aa 20–37), the light red box
represents the glycosyl transferase domain (aa 188–374), and the light blue box represents the ricin-B-lectin domain (aa 497–630). The shaded
area represents the glycosyl transferase superfamily domain (aa 163–496).
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Tumoral calcinosis is extremely rare in infancy; only
21 cases have been described in the literature [16,50-54],
and of these only three previous cases have been associ-
ated with elevated serum phosphate levels [16,55,56].
The genetic mutations of previously described cases are
unknown. Subject 2 had subcutaneous tumors on her
scalp at the age of three weeks, which may have been the
first manifestations of HFTC in this patient, with new
tumors developing on her gluteal area at six years and
thigh at seven years. There are examples of asymptomatic
hyperphosphatemic children, who developed HFTC some
years after hyperphosphatemia was first identified [57],
and in one family, a small child, with homozygous muta-
tion in FGF23, was hyperphosphatemic but asymptomatic,
in contrast to her older sister with HFTC [17]. Our review
of the literature shows that HFTC and HHS rarely mani-
fested before the age of two years, with 78% of cases pre-
senting between two and 13 years of age. The symptoms
displayed in subject 2 in infancy may reflect GALNT3 as-
sociated HFTC. This condition may be under-diagnosed
in small children.
In our family, the clinical picture was complex and var-
ied significantly with age. Band keratopathy, not previously
reported in GALNT3 associated HFTC or HHS, was found
in the female at age 52. Eye involvement, with irritated,
itchy eyes, has been present in both siblings since early
childhood, but visual acuity has not been affected. There is
only one previous report of band keratopathy associated
with HFTC, but in that case the mutation was not known
[58]. Reported eye manifestations in HFTC and HHS also
includes calcifications on the eyelids, conjunctiva and the
peripheral cornea [11,18-20] as well as angioid streaks of
the retina [19,21,22]. Angioid streaks represent linear
breaks in areas of calcification of the Bruch’s membrane
separating the retina from the choroid, and may be com-
plicated by retinal detachment are typically found in pseu-
doxanthoma elasticum, a disorder of ectopic calcification.
Conjunctival and corneal calcification (CCC) is a well-
known manifestation of metastatic calcification in end
stage renal disease (ESRD) [59]. CCC occurs when the
level of calcium and phosphate in tears approach their
solubility product. As tears evaporate, and the fluid is
concentrated, the result is deposition of calcium-phosphate
salts on the corneal surface in the exposed interpalpebral
region. It is most often located in the perilimbal region,
and does not affect visual acuity. However, the most severe
form, band keratopathy, can lead to visual impairment. In
ESRD, the severity of CCC is positively correlated to the
serum level of phosphate and the serum calcium × phos-
phate product, but not serum calcium levels [60,61]. CCC
is also positively correlated to the occurrence of vascular
calcification in ESRD [61]. The mechanisms of conjunctival
and corneal calcifications are probably the same in HFTC
and HHS, with a high calcium × phosphate product in
serum and also other body fluids, such as tears. Our fe-
male subject is the first reported case of band keratopa-
thy in GALNT3 associated HFTC and HHS, and this
outcome is probably the result of 50 years of untreated
hyperphosphatemia.
Both our subjects have had severe dental involvement.
From childhood their dental roots have been reported as
abnormally short and bulbous, and from about 25 years
age, their teeth started falling out despite good oral hygiene
and regular dental care. Typical dental findings in HFTC
and HHS are short, abnormal roots and obliteration of the
root canals and pulp chambers. The lesions only partly re-
semble dentin dysplasia type I and II [23,24], and the specific
dental lesion has been suggested as a phenotypic marker of
HFTC [62].
The female had pain and stiffness in her hands and feet
going on for several years, along with other diffuse symp-
toms, suggesting a rheumatologic disease. Thorough work-
up failed to find an explanation, however, and the diagnosis
of HFTC/HHS was not suspected until a calcified tumor
Table 3 Review of the literature [3,4,7,8,11,16-49]
Phenotype Total Genotype Sex1
GALNT3 FGF23 KL Male Female
N (%) N (%) N (%) N (%) N (%) N (%)
Total 56 (100) 42 (75) 13 (23) 1 (2) 30 (54) 25 (46)
Male 29 (54) 22 (52) 8 (64) 0 (0)
Female 25 (46) 20 (48) 5 (36) 1 (100)
HFTC 30 (54) 22 (52) 8 (62) 0 18 (60) 12 (48)
HHS 6 (11) 6 (14) 0 0 3 (10) 3 (12)
HFTC + HHS 20 (36) 14 (33) 5 (39) 1 9 (30) 10 (40)
Dental involvement 22 (39) 18 (43) 3 (23) 1 13 (43) 8 (32)
Vascular calcification 10 (18) 6 (14) 3 (23) 1 3 (10) 6 (24)
Eye involvement 9 (16) 7 (17) 2 (15) 0 6 (20) 3 (12)
1Between-sex comparison for GALNT3 and FGF23 mutation only.
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arose in the male. This points to some important features
of this disease: firstly, it is very rare, and even more so in
Caucasians, and many clinicians will not be familiar with
the symptoms and signs of the disease. This can lead to de-
layed diagnosis, as well as lack of recognition of complica-
tions of the disease. Second, in HFTC, there are often long
symptom free intervals. This is most likely not associated
with phosphate lowering treatment, but a feature of the
disease [25].
In the first of her two pregnancies, the medical record
describes pronounced placental calcifications. Placenta cal-
cifications have not previously been reported in GALNT3
associated HHS/HFTC. However, placental calcifications
was also reported in a Caucasian female with HFTC [19] in
whom genetic analysis later revealed mutation in FGF23
[63]. Immunohistochemistry has shown a strong level of
antibody staining for GalNAc-T3 in the Golgi apparatus
and nuclei of normal human trophoblastic cells [64], and
recent reports show evidence for the expression of the
FGF receptor and its cofactor α-klotho in murine pla-
centa [65]. These observations may support the hypoth-
esis that HFTC/HHS may be associated with placenta
calcifications. However, further studies are needed to
examine the prevalence of placenta calcifications and
possible placenta failure in human GALNT3 and FGF23
associated HFTC/HHS.
The female had age-inappropriate thyroid calcifications,
but no clinical or biochemical symptoms or signs of thyroid
dysfunction. This same feature has been described in one
previous case of HFTC due to GALNT3 mutation [26].
Both subjects had low levels of plasma intact FGF23
and elevated levels of c-terminal FGF23. This is in con-
cordance with previous findings in HFTC and HHS,
although in our cases the results deviated less from nor-
mal than in previously reported cases (Additional file 1:
Table S1). GALNT3 encodes the enzyme GalNacT3 re-
sponsible for O-linked glycosylation FGF23, thereby
preventing the break down and inactivation of the func-
tional full-length version of the protein [9]. Defective O-
glycosylation of FGF23 due to GALNT3 mutation, as well
as mutation in the FGF23 gene itself, will destabilize the
FGF23 protein and lead to increased levels of FGF23 break
down products. The level of c-terminal FGF23 will be in-
creased, whereas the level of intact FGF23 will be low or
inappropriately normal given the level of hyperphosphate-
mia. The explanation of the relatively less abnormal results
for our two subjects is not clear, but could be due to sam-
pling procedure, sample handling and transportation, or
the different kits used for the analyses, as well as large
inter-individual differences in FGF23 levels [66].
HFTC and HHS, previously described as separate entities,
are now recognized as different manifestations of the same
rare disease [4] of increased phosphate reabsorption from
the kidney proximal tubuli. Some subjects display features
of both phenotypes, whereas most have HFTC or HHS
[27]. Some authors suggest a correlation between the type
of mutation in the GALNT3 gene and the phenotype [28];
most cases of homozygous missense mutations tend to
have a HHS phenotype, while cases of homozygous non-
sense mutations have a phenotype of HFTC. In our cases,
however, the homozygous missense mutation has resulted
in a HFTC phenotype in the male, and a combined HHS/
HFTC phenotype in the female. Our review of all cases
of HFTC and/or HHS caused by mutations in GALNT3
showed that more cases than previously recognized had
symptoms of HHS in addition to HFTC, and that HFTC
seems to the dominating phenotype in males, while more
females than males have manifestations of both HFTC
and HHS. Our cases confirms the notion that there may
be an underestimate of the prevalence of subjects with
both phenotypes, as subject 2 in our material had symp-
toms of HFTC in infancy, and episodes of HHS in child-
hood, which remained unrecognized until the present
study was conducted. The explanation for the great vari-
ation in phenotype, also within the same family, is not
clear, and influence from different factors regulating calci-
fication needs further clarification.
Conclusion
We have described HFTC and HHS in a consanguineous
Caucasian family with a novel GALNT3 mutation, dem-
onstrating new phenotypic features and significant vari-
ability in the natural course of the disease. A review of
the literature shows that more subjects than previously
recognized have a combined phenotype of HFTC and HHS.
HHS and HFTC are two characteristic phenotypes in a
spectrum of GALNT3 mutation related calcification
disorders, where the additional factors determining the
phenotypic expression, are yet to be clarified.
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